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Abstract
The recent epidemics of metabolic diseases, obesity, type 2 diabetes(T2D), liver lipid disorders 
and metabolic syndrome have largely been attributed to genetic background and changes in diet, 
exercise and aging. However, there is now considerable evidence that other environmental factors 
may contribute to the rapid increase in the incidence of these metabolic diseases. This review will 
examine changes to the incidence of obesity, T2D and non-alcoholic fatty liver disease (NAFLD), 
the contribution of genetics to these disorders and describe the role of the endocrine system in 
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these metabolic disorders. It will then specifically focus on the role of endocrine disrupting 
chemicals (EDCs) in the etiology of obesity, T2D and NAFLD while finally integrating the 
information on EDCs on multiple metabolic disorders that could lead to metabolic syndrome. We 
will specifically examine evidence linking EDC exposures during critical periods of development 
with metabolic diseases that manifest later in life and across generations.
Keywords
endocrine disruptors; obesogens; metabolism disruptors; developmental origins of health and 
disease; obesity; diabetes; lipid disorders
1. Introduction
Metabolic syndrome (MetS) is a complex condition characterized by insulin resistance, 
abdominal obesity, dyslipidemia, hypertension, and hyperglycemia; it is a risk factor for 
cardiovascular disease, T2D, stroke, chronic kidney disease and cancers [1, 2]. Its prevalence 
is increasing along with the increase in obesity, and it is reaching epidemic proportions 
affecting between 24% and 34% of the adult US population [3].
In the medical community, epidemics of metabolic diseases have largely been attributed to 
genetic background and changes in diet, exercise and aging. However, there is now 
considerable evidence that other environmental factors may contribute to the rapid increase 
in the incidence of obesity, T2D and other aspects of MetS observed over the past three 
decades [4]. One environmental factor that has begun to receive attention is a class of 
chemicals that can interfere with the action of hormones including metabolic hormones. 
These compounds, termed EDCs, are found in a wide variety of consumer products, and 
exposures are often widespread [5] Of particular concern is evidence that exposure to EDCs 
during critical periods when adipocytes are differentiating and the pancreas, liver, brain, etc. 
are developing can induce effects that manifest later in life, often as overt disease.
This review will examine changes to the incidence of obesity, T2D and NAFLD and its 
associated hyperlipidemia, the contribution of genetics and describe the role of the endocrine 
system in these metabolic disorders. It will then specifically focus on the role of EDCs in 
metabolic diseases, focusing on their role in the etiology of obesity, T2D and NAFLD while 
finally integrating the information on EDCs on multiple metabolic disorders that could lead 
to MetS. We will specifically examine evidence linking EDC exposures during critical 
periods of development with metabolic diseases that manifest later in life and across 
generations.
2. Metabolic Diseases
2.1 Obesity
Obesity is a global epidemic that affects infants, children and adults [6]. The global 
prevalence of obesity has nearly doubled over the past three decades and in the US it is the 
highest recorded in human history [7]. For the first time worldwide, the number of obese and 
overweight people is greater than the number of those who are underweight [8]. This 
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dramatic increase in the rate of abdominal obesity has been observed in both developed and 
developing countries [9, 10].
Obesity among children and adolescents has similarly increased [6]. Approximately one 
third of US children are overweight or obese, and over 60% of obese children will become 
obese adults [11]. There is also an obesity epidemic among infants six months of age and 
younger; an age group where food choices and limited physical activity cannot explain this 
outcome [12].
The obesity epidemic is not limited to humans but has also been observed as upward trends 
in body weight among primates and rodents living in research colonies, as well as among 
feral rodents, horses and domestic dogs and cats [13].
Staggering health care costs are associated with treating the co-morbidities that typically 
accompany obesity [14] including cardiovascular disease, hypertension, dyslipidemia, liver 
and gallbladder disease, insulin resistance, hyperglycemia and T2D [9]. Obesity is also 
associated with neurodegenerative diseases, cancers and obstructive sleep apnea. Thus, 
determining the factors that contribute to obesity has become a major public health issue.
2.2 Type 2 Diabetes
The American Diabetes Association (ADA) defines Diabetes Mellitus (DM) as: “a group of 
metabolic diseases characterized by hyperglycemia resulting from defects in insulin 
secretion, insulin action, or both” [15]. DM can result from a deterioration in function and/or 
a loss of mass of pancreatic tissue [16] . T2D (formerly known as adult-onset or non-insulin-
dependent diabetes or DM) accounts for 90-95% of diabetes cases and is characterized by 
increased insulin resistance and pancreatic beta cell dysfunction. More than 11% of 
individuals in the US older than 20 have diagnosed or undiagnosed T2D [7] and another 
35% are estimated to be pre-diabetic. The World Health Organization (WHO) estimates that 
347 million people globally suffer from diabetes (90% of which is T2D) [17]. Adolescents 
and even children have experienced significant increases in the prevalence of this disease 
over short periods [14, 18].
Obesity is the main environmental factor driving the increased incidence of T2D; 70% of the 
risk associated with T2D is related to weight gain. Obesity is associated with insulin 
resistance that promotes beta cell proliferation, leading to hyperinsulinemia typical of early 
stages of T2D and MetS. However, obesity is neither necessary nor sufficient to cause T2D; 
these conditions can occur independently. Indeed, 20% of adults with T2D were not 
overweight and 57% of obese individuals do not have T2D [19].
2.3 Nonalcoholic Fatty Liver Disease and Hyperlipidemia
Liver is the central organ for lipid metabolism. Nonalcoholic fatty liver disease (NAFLD), 
characterized by excess triglyceride accumulation within hepatocytes, or steatosis, is 
considered by some to be the hepatic manifestation of obesity and MetS. NAFLD is the most 
common liver disease, and it affects 25% of the global population [20] and almost 8% of 
children [21]. NAFLD and its more severe form, nonalcoholic steatohepatitis (NASH), are 
associated with increased liver-related and overall mortality [20], and NAFLD is a risk factor 
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for cardiovascular disease [22]. The metabolic condition most commonly associated with 
NAFLD is hyperlipidemia (69%), although NAFLD is also associated with obesity (51%), 
MetS (43%) and T2D (23%) [20]. NAFLD was initially thought to occur predominantly in 
women [23] but increasing evidence indicates that males and perhaps post-menopausal 
females are more susceptible to NAFLD [21, 24].
Hyperlipidemia is an elevation in blood triglycerides (hypertriglyceridemia), cholesterol 
(hypercholesterolemia), phospholipids, or a combination thereof. While there is an 
association between NAFLD and hyperlipidemia, not all patients with one disorder are 
affected by the other. The prevalence of hypertriglyceridemia in US adults is 25%, although 
it declined from 33% in 2001-2004 [25]. Total and LDL cholesterol have also been 
declining, and these favorable changes may be attributed to increased awareness and 
utilization of lipid lowering medications [26]. Among adolescents and US children, the 
prevalence of hyperlipidemia was 20% (1999-2012) [27].
2.4 Metabolic Syndrome
The International Diabetes Federation estimates that 20-25% of the world’s adult population 
have MetS, which it defines as: “a cluster of the most dangerous heart attack risk factors: 
diabetes and prediabetes, abdominal obesity, high cholesterol and high blood pressure” 
(https://www.idf.org/metabolic-syndrome). The etiology of MetS is still a matter of research 
but insulin resistance and central obesity are significant contributors. Although there is still 
substantial debate, it is likely that components of MetS arise from insulin resistance. When 
insulin resistance occurs, there is an increase of fasting glucose and impaired glucose 
tolerance, often due to the abnormal expression of gluconeogenic enzymes. This metabolic 
state induces further insulin release, ultimately resulting in hyperinsulinemia. 
Hyperinsulinemia then simulates transcription factors such as Srebp-1c in the liver, which 
drive hypertriglyceridemia and hepatic steatosis [28]. In addition, the overproduction and 
secretion of insulin by pancreatic β-cells can result in their exhaustion and death, initiating 
the onset of T2D. The most prevalent form of insulin resistance is associated with abdominal 
obesity and dysfunction of adipose tissue, indicating an important central role for obesity in 
MetS.
2.5 Genetic Contributions to Metabolic Diseases
2.5.1 Genetic Factors in Obesity—While the hereditary origins of obesity have long 
been assumed, a genetic contribution to obesity became evident only in the last two decades 
[29]. Evidence from twins and animal studies indicates that genetic factors account for 
40-70% of the variation in BMI [30-33]. Although several single genes are linked to obesity, 
studies have confirmed that the genetic basis of high BMI is mainly polygenic (i.e., resulting 
from polymorphisms in several genes that are associated with appetite and metabolism) or 
results from single nucleotide polymorphisms [SNPs] rather than a single gene mutation 
[34]. Three SNPs are significantly related to obesity: one in FTO (fat mass and the obesity-
associated gene), one near TMEM18 (transmembrane protein 18) and one near MC4R 
(melatocortin 4 receptor) [29, 34-36]. Only rare forms of obesity, usually parts of genetic 
syndromes, result from a single gene mutation or chromosomal abnormalities such as 
Prader-Willi and Bardet-Biedl syndromes [37]. Because many people who carry genetic 
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variants linked to increased BMI are not obese, it is anticipated that other environmental 
factors can influence these genetic predispositions.
2.5.2 Genetic Factors in Diabetes—Genetic factors are involved in the development of 
both type 1 and T2D. The most prominent genetic factor known to be associated with type 1 
diabetes is located in the region of chromosome 6 that contains the highly polymorphic HLA 
class II genes and controls immune responsiveness [38]. Recently, whole-genome 
investigations have detected more than 20 other genetic variants associated with type 1 
diabetes [39].
Twin and family studies have provided strong evidence that T2D also has a solid genetic 
predisposition [40-42]. Genome wide association studies (GWAS) identified genetic variants 
associated with T2D; most of the loci identified are related to lipid metabolism, obesity and 
β-cell pathways [43, 44]. TCF7L2 demonstrated the strongest effect of >70 loci associated 
with the disease [43]. Similar to the genetic basis for obesity, it is assumed that 
predisposition to T2D involves multiple genes and SNPs.
2.5.3 Genetic Factors in Lipid Disorder Metabolism—Genetic predisposition to 
several lipid metabolism disorders was demonstrated based on twin and family studies with 
estimates that 40% to 80% of the variance in blood lipid levels results from genetic 
polymorphisms [45-47]. Familial hypercholesterolemia is an autosomal dominant disease 
characterized by elevated blood low-density lipoprotein levels (LDL). More than 150 
mutations in the LDL receptor gene and in genes encoding the proteins apolipoprotein B 
(APOB), proprotein convertase subtilisin/kexin type 9 (PCSK9) and low density lipoprotein 
receptor adaptor protein 1 (LDLRAP1) that interact with the LDL receptor, are associated 
with the disease [48, 49].
High levels of very low-density lipoprotein (VLDL) and triglycerides characterize 
hypertriglyceridemia. The hereditary form of this disease can result from mutations in genes 
that regulate the metabolism of triglyceride rich lipoproteins such as apolipoprotein A5 
(APOA5) LPL, apolipoprotein C2 (APOC2), lipase maturation factor-1 (LMF1) and 
glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 
(GPIHBP1). Hypobetalipoproteinemia is an autosomal dominant disease associated with low 
levels of LDL cholesterol and APOB-containing lipoproteins. Mutations in APOB and 
PCSK9 genes are common among patients [50].
2.5.4 Genetic Factors in NAFLD—Genetics have also been shown to contribute to 
variability in the occurrence of NAFLD [51]. In recent years, GWAS have identified two 
major genetic determinants associated with NAFLD. The most significant genetic linkage 
identified to date is a SNP in the gene patatin-like phospholipase domain-containing 3 
(PNPLA3), a gene involved in the remodeling of hepatocellular lipid droplets [52]. This 
variant alters the mobilization of fatty acid, inhibits the activity of lipases and can cause 
hepatocellular accumulation of triglycerides [53]. Carriers of this genetic variant have 
increased susceptibility to liver damage when exposed to environmental stressors [53]. 
Another SNP in transmembrane six superfamily member 2 (TM6SF2) has been linked with 
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NAFLD. This gene variant is located on chromosome 19 and associated with increased 
hepatic triglyceride content and lower serum lipoproteins [54, 55].
3. Overview of Tissues and Hormones Controlling Metabolism
The endocrine system controls the tissues and organs that regulate weight and metabolism. 
Hormones and growth factors including estrogens, androgens, glucocorticoids, insulin and 
thyroid hormones (among others) regulate the pathways that control the number and content 
of adipocytes as well as appetite, satiety and energy balance [56-59]. Other hormones affect 
metabolism via actions in the gastrointestinal tract [ghrelin, cholecystokinin (CCK), 
glucagon like peptide (GLP-1)], the pancreas (insulin, glucagon), muscle (insulin), liver 
(glucagon, insulin, FGF21), adipose tissue (leptin, adiponection, and a variety of other 
factors), immune system, and brain [Neuropeptide Y (NPY), agouti related protein (AgRP), 
pro-opiomelanocortin (POMC), alpha melanocyte-stimulating hormone (alpha MSH)] 
[56-60]. These and other hormones, growth factors and neurotransmitters control the 
hedonic pathways in the brain that regulate food reward mechanisms, food cravings and 
addiction [61-63]. They also control glucose and lipid levels via pancreatic, muscle and liver 
responses. The pancreas responds to rising blood glucose levels by releasing insulin, which 
then promotes glucose uptake into tissues. It also responds to falling glucose levels in the 
blood by releasing glucagon, which acts on the liver to stimulate glycogenolysis and 
gluconeogenesis to raise blood sugar. The liver also regulates glucose and lipid metabolism 
via a number of nuclear hormone receptors including aryl hydrocarbon receptor - AhR, 
pregnane x receptor - PXR, and the constitutive androstane receptor – CAR.
Below we focus on the endocrine control of adipogenesis, glucose homeostasis and liver 
lipids.
3.1 Neuroendocrine Control
The neuroendocrine hypothalamus, together with some structures in the brainstem, plays a 
key role in the regulation of energy balance through the integration of peripheral signals and 
onward signal transmission (Figure 1). Peripheral signals conveying information about meal 
processing, gastrointestinal activity, and changes in energy stores access the brain via a 
number of routes, crossing or by-passing the blood-brain barrier from the systemic 
circulation, or changing the firing rate of vagal or other sensory nerve fibers. In the medulla, 
the nucleus of the solitary tract and the area postrema are key sites for the integration of 
these peripheral signals and for sending them to other integration sites located in the 
hypothalamus (for reviews see [64, 65]).
The hypothalamus participates in the regulation of food intake and body weight with two 
neuroendocrine components: the afferent peripheral system (stimulated in response to a 
meal) and the efferent system (regulating the feeding behavior and energy metabolism) [66, 
67]. The peripheral signals are the hormones insulin (secreted by the endocrine pancreas in 
response to changes in blood sugar), leptin (secreted by adipocytes in proportion to fat 
mass), ghrelin and orexin-A (secreted by the stomach and the gut)[68]. These hormones link 
the control of peripheral energy metabolism to the feeding behavior integrating neural units 
by modulating short term signals that determine meal initiation and termination as well as 
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energy balance [69]. Two neurochemically-distinct populations of hypothalamic neurons 
located in the arcuate nucleus (ARC) are critical for the integration of signals of nutritional 
status, and influence energy homeostasis [70]. One neuron group expresses the potent 
orexigenic neuropeptide NPY and AgRP and shows high concentrations of binding sites for 
many hormonal and metabolic signals such as insulin, leptin and ghrelin [71]. An increase in 
NPY release results in increased food intake and decreased energy expenditure. Another set 
of ARC neurons expresses the neuropeptide precursor POMC, which is processed to 
melanocortin peptides; activation of these neurons decreases food intake and increases 
energy expenditure [72-74]. These two populations of neurons thus exert opposite effects on 
energy intake and interact on several levels. The current hypothesis is that as adipose stores 
increase, both insulin and leptin levels increase along with POMC expression, while NPY 
synthesis and activity are inhibited and food intake is reduced. Conversely, when NPY 
synthesis and release are increased and POMC is decreased, the result is an increase in food 
intake [75-77]. Dysfunction of the NPY system has been implicated in obesity and T2D in 
humans [78, 79]
Peptidergic neurons in the ARC project to other hypothalamic nuclei such as the 
paraventricular nucleus (PVN), dorsomedial hypothalamus, lateral hypothalamic area 
(LHA), and perifornical area [80, 81]. These secondary centers process information 
regarding energy homeostasis. In particular, the PVN receives NPY/AgRP and POMC/
METSH/CART projections and contains secondary neurons which are involved, for 
instance, in emotional and stress responses, which have been shown to be physiologically 
involved in energy homeostasis (i.e. thyrotropin releasing hormone (TRH) and corticoid 
releasing factor) [82]. In addition, the liver (an important integrator of nutrient metabolism) 
produces an endocrine satiety signal (fibroblast growth factor 21, FGF21), that suppresses 
the consumption of simple sugars, and reduces sweet-seeking behavior, by acting centrally 
at the level of the PVN [83].
Estradiol, in addition to its function as a gonadal hormone, is involved in the regulation of 
metabolism through the modulation of food intake, body weight, glucose/insulin balance, 
body fat distribution, lipogenesis and lipolysis, and energy consumption. The central 
metabolic action of estradiol at the brain level occurs primarily in the ARC of the 
hypothalamus where it targets directly the POMC neurons and indirectly the NPY cells [84]. 
Estradiol represses the synthesis of NPY and AgRP and thereby has an inhibitory function 
on food intake [85-88]. Recent data have shown that leptin and estradiol may use a common 
pathway to regulate energy metabolism, namely the STAT3 pathway in POMC neurons [87, 
88].
This integrated pathway between reproductive and metabolic functions is confirmed by 
recent findings on the role of brain kisspeptin and its receptor KISS1R (reviewed by [89]), 
originally identified based on their endocrine functions of regulating puberty and fertility, 
through actions on hypothalamic gonadotropin releasing hormone production [90]. 
Emerging evidence demonstrates a significant role of kisspeptin for regulating glucose 
homeostasis, insulin secretion, as well as food intake and body composition [91], with 
deficient kisspeptin signaling resulting in decreased locomotor activity and increased 
adiposity in a sex-dependent manner [92]. Organization and function of the kisspeptin-
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Kiss1R system is sex-specific, and sex steroid hormones play a crucial role in determining 
such sexual dimorphisms [93, 94]. The kisspeptin system is therefore a potential target of 
endocrine disruption; in rodent studies, exposure to EDCs altered the kisspeptin system in a 
region-, sex- and compound -specific manner, and induced effects on the timing of pubertal 
onset, estrous cycles, and socio-sexual behaviors [95-97].
3.2 Adipose Tissue
Adipose tissue is the key regulator of energy balance and nutritional homeostasis and 
consists of white, brown and beige fat. It is an endocrine organ with more than 20 endocrine, 
paracrine and autocrine secretions. The adipose tissue consists of several depots located in 
subcutaneous, intra-abdominal (visceral) and intra-thoracic areas. Visceral adipose tissue 
depots are metabolically different from subcutaneous compartments [98]. Intra-abdominal 
(visceral) depots are associated with T2D and cardiovascular disease while subcutaneous 
depots seem protective against these diseases [99].
White adipose tissue stores energy as triglyceride and also signals to other organs on the 
status of energy reserves via hormones, growth factors and cytokines [100]. Two major 
secretions of white adipose tissue are leptin and adiponectin. Leptin is secreted in proportion 
to fat mass; it acts on the brain to reduce food intake and increase energy expenditure. 
However, obese individuals typically have increased serum leptin levels due to leptin 
resistance [101]. Adiponectin is also secreted from adipose tissue and induces fatty acid 
oxidation in liver, improves pancreatic beta cell function, enhances peripheral insulin 
sensitivity, suppresses hepatic glucose production and reduces inflammation [102]. Adipose 
tissue also contains immune cells, from both the adaptive (B and T lymphocytes ) or innate 
( macrophages) immune system thus it is an immune orgain. Obesity is considered a 
proinflammatory condition in which both hypertrophied adipoctyes and resident immune 
cells produce and release proinflammatory cytokines, including IL-6 and TNFα, which are 
associated with chronic low-level systemic inflammation, insulin resistance and T2D. In 
contrast, in non-obese individuals anti-inflammatory cytokines including adiponectin, 
interleukin −10, and transforming growth factor beta (TGFb) are preferentially secreted 
which, among other functions, improve insulin sensitivity [103].
Brown adipose tissue is present throughout life, but with highest volume in newborns. It 
generates body heat via non shivering thermogenesis while beige fat appears to be 
bifunctional, changing to either white or brown fat depending on the stimuli [104]. The 
sympathetic nervous system controls lipolysis in white adipose cells and stimulates the cold 
response in brown adipocytes.
In response to excess energy, adipocytes enlarge and/or increase in number [100]. Excess fat 
in these cells results in tissue dysfunction which leads to the development of other diseases 
and conditions including inflammation, T2D, heart disease, fatty liver, reproductive 
problems and some forms of cancer depending somewhat on the site of the added adipose 
tissue (e.g. visceral or subcutaneous) [100].
In humans, adipose tissue develops by the 14th week of gestation [105] followed by a second 
period of increased cellularity that continues after birth and lasts through adolescence [106]. 
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The number of white adipocytes is usually fixed after that time [100] however adipocytes are 
replaced at a rate of about 10% per year in adulthood [106], thus the tissue is not static. In 
mice, most subcutaneous adipogenesis occurs late in gestation and after birth; differentiation 
of gonadal fat only appears postnatally between birth and puberty [107]. Overall, fat mass 
can continue to grow due to high fat feeding which induces both hyperplasia and 
hypertrophy in rodents [107] with the hyperplasia occurring in the visceral tissue. Adult 
mice that are challenged with a high fat diet accumulate fat by hypertrophy in most adipose 
depots, with the exception of gonadal (visceral) fat which possesses higher capacity to 
expand by hyperplasia [107].
Specific genes play critical roles in fat cell development and control, including PPARγ and 
Runx2, often called the master regulators of fat cell differentiation [108] and sirtuins which 
play important roles in secretion of adipokines including leptin and adiponectin, hepatic 
glucose metabolism, insulin sensitivity and inflammation [109].
Adipocytes are derived from mesenchymal stem cells (MSCs), which can be 
neuroectodermal or mesodermal depending on where the fat body originates; differentiation 
of adipocytes requires a committed pre-adipocyte progenitor [110, 111]. Visceral white 
adipose tissue (WAT) is primarily derived from the lateral plate mesoderm [112], brown fat 
is largely produced by the paraxial mesoderm [113] , and cranial WAT from the neural crest 
[114] . Beige (a.k.a brite) fat arises from WAT (precursors or mature cells). Despite this 
common origin, beige fat is thermogenic, like brown fat, so it plays a different metabolic 
role than WAT and has a correspondingly different transcriptional program than WAT [115] 
[116]. Mesenchymal stem cells harvested from adipose tissue or bone marrow can be made 
to differentiate into fat, bone, cartilage, and other lineages in culture [117]; commitment to 
each of these lineages is largely mutually exclusive and irreversible [118]. Transformation of 
an MSC into an adipocyte requires initial commitment to the adipose lineage, followed by 
terminal differentiation into a mature adipocyte (reviewed in [100, 111]). Adipocyte 
commitment is mediated by transcription factors Zfp423 [119], Zfp467 [120], Schnurri2 
[121], Tcf7l1 [111] and the mTORC1 effector S6K1 [122]. Collectively these genes function 
to sensitize cells to BMP2/4 signaling while inhibiting canonical Wnt signaling and 
promoting expression of the so-called master regulator of adipogenesis, PPARγ. Terminal 
differentiation is primarily controlled by PPARγ and CCAAT-enhancer-binding proteins (C/
EBP) −α, −β, and −δ [123, 124] which establish a sustained feedback loop. Treatment of 
committed pre-adipocytes with an "adipogenic cocktail” (glucocorticoids, cAMP agonists, 
and insulin) increases expression of PPARγ and C/EBP proteins and is marked by induction 
of metabolic genes and adipokines associated with mature adipocytes [124, 125].
3.3. Control of Glucose Homeostasis
Regulation of blood glucose within the normal range is accomplished through the concerted 
action of several organs: glucose absorption by the intestine, glucose-dependent secretion of 
insulin and glucagon from the endocrine pancreas, regulation of glucose production by the 
liver, and glucose uptake and metabolism by peripheral tissues. All these processes are 
further regulated by the neural system.
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3.3.1Pancreas—The endocrine pancreas is comprised of the pancreatic islets of 
Langerhans, a heterogeneous population of 1000-3000 cells, where the predominant cell 
type is the insulin-releasing β-cell. Other cells include α-cells, responsible for glucagon 
secretion, and δ-cells, responsible for somatostatin release, pancreatic polypeptide-
producing cells (PP-cells) and ε-cells that produce ghrelin [126, 127]. While β- and α-cell 
populations represent about 70-80% and 20% respectively of the total islet cell number in 
rodents, in humans the pancreas is comprised of 40-45% α-cells and 50% β-cells [128] and 
up to 10% δ-cells.
The number of β-cells rapidly expands in utero and in the neonatal period and then 
replication occurs only at very low levels in adult rodents [129] and humans [130]. β-cells 
replicate throughout life after physiologic challenges like high blood sugar, peripheral 
insulin resistance and pancreatic injury and their mass is controlled by insulin, placental 
lactogen and prolactin (reviewed in [131]). The liver may also control β-cell proliferation via 
a novel hormone, betatropin [131], which is upregulated in pregnancy and in the ob/ob and 
db/db diabetic mouse.
The regulation of blood glucose starts when glucose is taken up by β-cells where it 
undergoes intermediary metabolism. Insulin release takes place after glucose metabolism 
increases the ATP/ADP ratio, which closes plasma membrane ATP-sensitive K+ (KATP) 
channels that are responsible for the resting membrane potential. This results in cellular 
depolarization and ultimately insulin release from the cell. Insulin secreted into circulation 
then binds to receptors on the surface of target cells in the periphery to facilitate glucose 
uptake and metabolism. Impaired β-cell insulin production results in a rise in blood glucose 
levels that over time can lead to the development of diabetes (See figure 3). This metabolic 
transition can arise from frank β-cell destruction as seen in type 1 diabetes or to β-cell 
dysfunction arising from increased synthetic demand resulting from peripheral insulin 
resistance as in T2D.
Glucagon is another key glucose-regulating hormone. It is secreted by α-cells in response to 
falling blood glucose levels and principally stimulates the liver to increase glycogenolysis 
and gluconeogenesis to raise circulating blood sugar [132, 133]. When extracellular glucose 
concentrations rise to levels required for insulin release, glucagon release decreases [134]. 
Several paracrine and neural mechanisms also inhibit glucagon release [127, 135-138]. 
While pure hyperglucagonemia is a rare cause of diabetes, disruptions in the autoregulatory 
feedback loop linking insulin and glucagon secretion is thought to result in inappropriate 
glucagon secretion in both type 1 and T2D [139].
3.3.2 Liver—The liver is the principal location of glucose storage as glycogen, and the 
main source of glucose for all tissues. Because the pancreatic veins drain into the portal 
venous system, every hormone secreted by the pancreas must traverse the liver before 
entering systemic circulation. The liver is a major target for pancreatic insulin and glucagon 
action as well as their site of degradation. In fact, 70% of hepatic glucose output occurs via 
liver glycogenolysis and 30% via gluconeogenesis.
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Insulin promotes glycogen synthesis and decreases its breakdown after enhancing the 
transcription of glucokinase and the activation of glycogen synthase through changes in its 
phosphorylation state. Insulin increases transcription of the glucokinase gene and other 
enzymes involved in glycolysis such as phosphofructokinase and pyruvate kinase, promoting 
glycolysis [140]. Insulin also inhibits gluconeogenesis by decreasing phosphoenolpyruvate 
carboxykinase (PEPCK) and fructose-1, 6-biphosphatase (FBPase) gene expression. As a 
result, insulin inhibits glucose production during the fed state, keeping glucose levels within 
the normal range. At the same time, high glucose levels inhibit glucose-6-phosphatase and 
decrease the activity of glycogen phosphorylase; all together, these processes considerably 
reduce the conversion of glycogen to glucose.
Insulin also promotes the storage of fat by stimulating lipogenesis. It inhibits the oxidation 
of fatty acids by decreasing fatty acid transport into the mitochondria. Additionally, insulin 
stimulates fatty acid synthase (FAS). All together, these pathways promote the formation of 
triglycerides that can either be stored in the liver or exported as very low density-
lipoproteins (VLDL).
On the other hand, glucagon signaling in the liver plays a key role during fasting, as well as 
in the adaptive response to hypoglycemia. After binding at its receptors, glucagon activates 
the cAMP/PKA pathway, which decreases glycolysis via a modulatory action on pyruvate 
kinase [127]. Glucagon increases gluconeogenesis after up-regulation of glucose-6-
phosphatase and PEPCK through the activation of coactivators such as CREB-binding 
protein (CBP), P300, PGC-1 and TORC2 [134, 141-144]. In addition, glucagon also 
activates ketogenesis. All these effects favor hepatic release of glucose to maintain normal 
blood glucose levels during fasting. Glucagon also promotes the oxidation of fat in the liver, 
increasing the activity of the citric acid cycle and the generation of ketone bodies. Moreover, 
there is a glucagon-induced decrease of triglyceride, VLDL, cholesterol and fatty acid 
synthesis mediated by PPARα [145].
3.3.3 Skeletal muscle—Skeletal muscle is the major site of insulin-mediated glucose 
usage; it can clear up to 70% of the blood glucose pool. Unlike the liver, glucose transport in 
skeletal muscle is insulin dependent via the recruitment of the glucose transporter GLUT4 to 
the membrane. Insulin activation of hexokinase and glycogen synthase enhances glycogen 
synthesis. Activation of phosphofructokinase and pyruvate dehydrogenase enhances glucose 
breakdown and oxidation. The action of insulin in glucose utilization allows the muscle to 
store fat as triglycerides that together with glycogen can be used as sources of energy during 
exercise and heat generation.
3.3.4 White adipose tissue—Similar to skeletal muscle, insulin promotes recruitment of 
GLUT4 to the membrane and accelerates glucose transport into adipocytes. It then induces 
the breakdown of glucose to generate triglycerides. These triglycerides are stored in fat 
together with those delivered via the circulation as chylomicrons and VLDL. In addition, 
insulin inhibition of triglyceride lipase decreases triglyceride breakdown. Insulin decreases 
lipolysis through inhibition of hormone sensitive lipase in a cAMP-dependent manner [146, 
147]. Insulin promotes the synthesis of lipoprotein lipase (LPL), which is exported to the 
endothelial cell plasma membrane. Once anchored there, LPL cleaves triglycerides from 
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VLDL and chylomicrons into glycerol and fatty acids that are taken up by nearby adipocytes 
to form triglycerides.
Although the role of glucagon in WAT is controversial, recent results point to a role in 
lipolysis [127]. This lipolytic action has been attributed to glucagon-induced release of 
fibroblast growth factor 21 (FGF21) [148] as well as to signals from the sympathetic nervous 
system [149].
3.3.5 Importance of Insulin Resistance—Insulin resistance is present in many cases of 
obesity and T2D. However, most insulin-resistant individuals do not develop hyperglycemia 
due to compensatory increases biosynthesis and the release of insulin as well as increases in 
pancreatic β-cell mass. For example, obese subjects secrete 2-5 times more insulin in 
response to glucose, while athletes secrete 2-5 times less insulin [150]. Insulin resistance 
developed during puberty and pregnancy is counteracted by adaptation of β-cell mass and 
function, with sex and maternal hormones playing important roles [151-155]. Insulin 
sensitivity, therefore, regulates β-cell function; insulin resistant subjects, whether they are 
obese or lean, have greater insulin response and lower insulin clearance than insulin-
sensitive individuals. In order for insulin resistance to lead to T2D, β-cells adaptation must 
fail [156]. Regulation of β-cell mass may occur by hypertrophy of existing cells and 
proliferation. Glucose, non-esterified fatty acids, incretins, and neuronal signaling are 
involved in increasing β-cell mass and function, yet when glucose and lipids are increased 
for longer than normal β-cell are killed which generates the onset of T2D [157, 158].
The ability of pancreatic β-cells to integrate responses to changes in insulin sensitivity likely 
involves increased metabolism and metabolic signals. These include signaling molecules 
from adipocytes (e.g. NEFAs signaling via GPR40) as well as and fatty acyl-CoAs that 
augment insulin release via the exocytotic machinery and protein kinase C (PKC). Leptin, 
adiponectin, and proinflammatory cytokines such as TNFα, IL-6 and monocyte 
chemoattractant protein (MCP-1) from macrophages and other cells infiltrating adipose 
tissue have a role as well [157]. Pancreatic α-cells are responsible for glucagon production 
and release. Thus alterations in the pancreatic α-cell function can also contribute to T2D 
[127]. Unlike β-cells, the mass of pancreatic α-cell does not decrease in T2D, resulting in an 
increased α-to-β cell ratio; this altered ratio also contributes to higher plasma levels of 
glucagon and therefore to hypoglycemia.
Thus, when β-cells are healthy, their adaptive responses counterbalance insulin resistance 
and preserve normal glucose tolerance. However, if β-cell dysfunction occurs due to genetic 
causes, environmental perturbations, or both, then the individual is more prone to develop 
impaired glucose tolerance, high fasting glucose levels, and ultimately T2D.
3.4 Liver Control of Xenobiotic and IntermediaryMetabolism
The liver is the largest and most metabolically complex organ in the human body. 
Hepatocytes make up over 80% of total liver mass and play a critical role in intermediary 
energy (lipid, carbohydrate, amino acid) and xenobiotic metabolism (Phase I-III 
metabolizing enzymes). Other liver-specific cell types include Kupffer cells, biliary 
epithelial cells, sinusoidal endothelial cells, and stellate cells. These cells have specialized 
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functions ranging from protection against infection, bile duct flow, endocytosis and fibrosis. 
The liver arises from the hepatic diverticulum of the foregut during the fourth week of 
gestation. Hepatoblasts are bipotential progenitor cells arising from foregut endodermal cells 
that differentiate into hepatocytes and cholangiocytes.
The liver is the principal organ for xenobiotic detoxification. Ligand-activated xenobiotic 
receptors induce foreign compound metabolism by cytochrome P450s. For example, the aryl 
hydrocarbon receptor (AhR) induces expression of CYP1A1, the constitutive androstane 
receptor (CAR) induces CYP2B10, and the pregnane X receptor (PXR) induces CYP3A4. In 
general, chemical ligands are metabolized by the P450s that they induce. In addition to 
foreign compound metabolism, xenobiotic receptors play an important role in the control of 
hepatic lipid and carbohydrate metabolism. It was recently proposed that activation and 
cross-talk of xenobiotic receptors by foreign compounds is a molecular initiating event in 
hepatic steatosis [159]. Likewise, interactions between environmental compounds and 
xenobiotic receptors regulate, in part, hepatic carbohydrate metabolism including 
gluconeogenesis and insulin resistance [160, 161]. These mechanisms appear to account for 
the wasting syndrome associated with some dioxin-like chemicals that activate the AhR 
[161].
Owing to its critical role in xenobiotic and intermediary metabolism, the liver is a principle 
target organ for chemicals resulting in the development of steatosis. Steatosis may progress 
to steatohepatitis (steatosis with superimposed hepatic inflammation), cirrhosis and 
hepatocellular carcinoma, and ultimately liver-related death if liver transplantation does not 
occur. In the clinic, steatohepatitis is named according to its etiology: alcohol (alcoholic 
steatohepatitis, ASH), cancer medications (chemotherapy associated steatohepatitis, CASH), 
excess dietary lipids or carbohydrates (NASH), and industrial chemicals (toxicant associated 
steatohepatitis, TASH) [162, 163]. While disease mechanisms vary by etiology [164], 
steatosis is invariable associated with an imbalance of hepatocyte lipid synthesis, oxidation, 
uptake, and efflux via VLDL [159].
3.5. Thyroid Control of Metabolism
The thyroid gland, located in the neck, is one of the largest endocrine glands in the body. It 
plays a crucial role in normal growth and development, energy homeostasis and regulation 
of adult metabolism. The main hormones secreted by the gland are Thyroxine (T4), which 
has limited biological activity and triiodothyronine (T3) which is more potent but with a 
shorter half-life. T4 is converted to T3 by the enzyme thyroxine 5'-deiodinase [165]. Thyroid 
hormones are regulated by thyroid stimulating hormone (TSH) secreted by the anterior 
pituitary gland, which in turn is regulated by TRH produced by the hypothalamus [166, 
167].
Tight interaction exists between thyroid function, weight control, and obesity [168]. Mild 
differences in thyroid function can be associated with changes in body weight and fat mass 
[168, 169]. Even small variations in serum TSH, within the reference range of the assay, 
were associated with differences in body mass; higher levels of TSH were associated with 
increased BMI [170-172]. There is an inverse correlation between free thyroxine (fT4) 
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values and body mass index (BMI), even when fT4 values remain in the normal range [173, 
174] .
3.6. Sexual Dimorphism and Metabolism
In humans, there are important sex differences in the incidence and health consequences of 
obesity; men and women differ in the patterns of fat deposition, fat mobilization, utilization 
of fat, and the consequences of both excess and insufficient fat stores. Gonadal hormones 
appear to play a crucial role in shaping such differences. Women suffer fewer obesity-related 
disorders than men do. In fact women are resistant to free fatty acid-induced insulin release 
and are therefore less prone to T2D before manopause but the prevalence of these disorders 
increases dramatically after menopause[175]. The prevalence of T2D is higher in men before 
puberty compared to reproductive age females. It is noteworthy that T1D has a male 
predominance as well[176]. Androgens, adiposity and disease are clearly interrelated in 
humans.
These asymmetries in energy balance traits probably reflect evolved adaptive differences due 
to differential investment and costs of reproduction in male and female mammals and are 
mainly shaped by gonadal hormones either during development (organizational effects) or at 
adulthood (activational effects) (for reviews see [177-179]). Development and maturation of 
brain circuits involved in the regulation of food intake and metabolism occur during the 
perinatal period. The current literature argues that there are multiple critical periods in which 
hormones organize energy balancing traits; besides the fetal and neonatal stage, the 
peripubertal period is also a time window when sexually dimorphic eating behaviors are 
established [180]. Sex differences in body fat composition and distribution, energy 
expenditure, orosensory physiology, taste and smell preference, food intake, binge eating, 
susceptibility to diet induced obesity, responses to leptin-, ghrelin,- or insulin-induced 
hyperphagia, POMC gene expression in the ARC nucleus, and many other traits are well 
documented (reviewed in: [181-183]).
The POMC, melanocortin system, is sexually dimorphic [184]. In adults, females have 
increased responsiveness to leptin and decreased responsiveness to insulin in comparison to 
males. These differences are estrogen dependent [185], and they are perinatally organized by 
testosterone [186]. The NPY/AgRP circuit is also sexually dimorphic. In particular, in situ 
hybridization studies demonstrated sex differences in the distribution of NPY mRNA-
containing cells in the rat ARC, and its modulation by testosterone in males [187]. Also, 
NPY immunoreactivity is sexually dimorphic in the ARC, the dorsomedial hypothalamus, 
and the PVN [188]; NPY-Y1 receptor expression is higher in females compared to males 
[189].
Male mice have higher levels of daily food intake, post-fast hyperphagia and leptin-induced 
hypophagia compared to female mice, and these behavioral differences are related to sexual 
dimorphisms in the ARC as far as the number of ARC cells containing NPY, AgRP, and 
POMC. Females perinatally treated with testosterone or DHT show male-like levels of food 
intake, post-fast hyperphagia and POMC gene expression and projection [186].
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Estrogens play a pivotal role in regulating energy homeostasis, especially in female 
mammals, either by acting directly on the brain or through activation of estrogen receptors 
(ER) on adipocytes. Estrogens protect against increased adiposity/obesity through their 
effects of suppressing appetite and increasing energy expenditure; estradiol suppresses 
feeding by enhancing the potency of other anorectic signals (leptin, apolipoprotein, BDNF, 
cholecystokinin) and by decreasing the potency of orexigenic signals such as ghrelin and 
melanin concentrating hormone [87, 185, 190, 191]. The liver is a major target for estrogen 
action in female mammals and the activity of the liver ERα is strictly associated with 
ovarian activity [192]. In the liver, ERα regulates fertility in response to protein 
consumption and controls lipid and cholesterol synthesis in relation to the reproductive cycle 
[193] . Since the liver is the major organ for the control of energy homeostasis, the activity 
of hepatic ERα also influences the synthesis and secretion of the signaling molecules 
necessary for coordinated responses among liver, fat, muscles and brain [192].
In mammals, including humans, the liver is a sexually dimorphic organ and exhibits major 
differences in the profile of steroid, lipid, foreign compound metabolism [194], and gene 
expression. These differentially expressed genes regulate a wide range of biological 
processes; accordingly, many enzymes, such as steroid hydroxylases belonging to the 
cytochrome P450 (CYP) superfamily, are expressed in the liver in unique, sexually biased 
patterns [195]. Such differences have implications for sex-related steroid metabolism, 
xenobiotic metabolism and pharmacokinetics, and differential susceptibility to some liver 
diseases [23, 196]. The sexual dimorphism of liver gene expression is established and 
maintained, in part, by the temporal pattern of pituitary GH secretion, which is sex specific 
in many species (episodic in males and more stable in females) [197]. GH secretion is 
affected by brain and lactotrope dopamine 2 receptors (D2Rs) [198]. A link exists between 
obesity, growth, and dopaminergic systems located within the central nervous system and in 
other tissues [199-201].
4. Environmental Contributions to Obesity, T2D, and Dyslipidemia
The global pandemic of obesity, T2D and MetS is often causally linked to marked changes 
in diet and lifestyle, namely increases in dietary intake of high energy diets and concomitant 
reduction in physical activity levels [202]. However, it is clear that the susceptibility to these 
diseases is not that simple. Indeed there have been multiple environmental factors that have 
been linked to the increase in these metabolic diseases including stress, lack of sleep, 
adenoviruses, childhood antibiotics [202-205] and exposure to environmental chemicals 
[206] . While all of these environmental stressors likely play some role in the epidemic of 
metabolic diseases, we focus here on exposure to environmental chemicals, especially EDCs 
and the role they might play in disease etiology. Indeed the current rise in metabolic diseases 
correlates with substantial increases in environmental chemical production and exposures 
over the past four decades [207-209].
4.1 Overview of Endocrine Disrupting Chemicals
In 2012, the Endocrine Society defined EDCs as “an exogenous chemical, or mixture of 
chemicals, that can interfere with any aspect of hormone action” [210]. This definition is a 
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more simplified version of the one originally proposed by the US EPA, that EDCs are “an 
exogenous agent that interferes with the production, release, transport, metabolism, binding, 
action, or elimination of natural hormones in the body responsible for the maintenance of 
homeostasis and the regulation of developmental processes” [211]. At the global level, the 
WHO/UNEP definition of EDCs is “an exogenous substance or mixture that alters the 
function(s) of the endocrine system and consequently causes adverse effects in intact 
organism, or its progeny or (sub) population [212]. Although EDCs were first identified as 
agonists or antagonists of estrogen, androgen and thyroid hormone receptors [213], EDCs 
disrupt hormonal signaling systems by interfering with a variety of hormones through 
numerous mechanisms. EDCs can disrupt normal hormone levels by inhibiting or 
stimulating the production and metabolism of hormones, or changing the way hormones are 
transported to target tissues.
The effects of EDCs, like those of hormones, can occur at very low levels [214-217]. Other 
principles of hormone action are similarly expected for EDCs including their ability to 
induce tissue- and time-dependent effects and strong evidence that responses to EDCs can be 
non-monotonic (often referred to as biphasic or U-shaped responses) [5, 210, 215, 218, 219]. 
Some EDCs are persistent and can bioaccumulate in tissues [220, 221]. With more than 
85,000 registered chemicals in commerce, most of which are poorly studied; current 
estimates have identified approximately 1000 chemicals that meet the criteria of an EDC 
[213, 222].
Decades of work from both basic and clinical endocrinology have revealed that the 
disruption of hormones can have detrimental effects on a variety of diseases [223] 
[223-225]. A number of recent “state of science” reviews of the EDC literature, as well as 
large reviews of hundreds or thousands of EDC studies, draw strong conclusions about the 
association between EDC exposures and diseases [210, 215, 218, 223, 226-229]. These 
conclusions are drawn from observational human epidemiology studies and controlled 
laboratory animal studies, as well as additional support from wildlife studies, in vitro 
mechanistic studies, and in silico studies. In 2015, a review of the EDC literature by 
scientists in the Endocrine Society found that there was strong evidence for a role of EDCs 
in the etiology of metabolic diseases, although these diseases were generally examined 
individually [230]. Some of these conclusions were challenged, with groups contesting the 
strength of evidence linking EDC exposures to endocrine-related diseases [231-236]. 
However, whereas some useful criticisms were put forward, these challenges typically 
resulted from a lack of understanding of the endocrine system, as well as of endocrine 
disruption as an effect on a complex regulatory network of the organism [219, 237-242]. On 
the contrary, the need to fully appreciate the impact of EDCs is apparent considering the 
health care costs associated with inaction [9, 229].
A number of relevant factors can influence whether significant effects are observed in 
experimental studies of EDCs and these factors can affect the strength of the evidence for an 
effect. First, measurement of body weight alone is now recognized to be an inadequate 
measure in experimental rodent studies to assess the effects of chemical exposure on 
adipocyte endpoints [243]. Second, the endocrine milieu of males and females is different, 
and thus it should be expected that sex-specific effects are often observed because of EDC 
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exposure, particularly for compounds that interfere with sex hormones. Third, the specific 
type of feed used in animal experiments can affect sex hormone levels in pregnant females 
and fetuses, and consequently result in significant differences in phenotype, including the 
potential to modify effects of chemical exposures [244, 245]. Indeed, natural diet 
components and EDCs may interact in several ways [246] .
One relevant challenge concerns the publication of apparently “conflicting” results on 
EDCs. Independent replication of results is the accepted standard for assessing validity of 
findings in research, thus the issue of non-replication of findings in some EDC studies must 
take into account the issues described above (sensitivity of endpoint, sex-specific effects, 
influence of animal feed), as well as the appropriate use of positive controls [247-249], [249, 
250], and /or negative control groups [251, 252], and the range of dose levels used [219, 
253]. There also appears to be a relationship between the source of funding and the 
likelihood of identifying effects of EDCs [238, 249, 254]. Thus, rather than labelling results 
as “conflicting” the factors involved in the apparent failure to replicate certain findings 
should be assessed [247, 255].
4.2 EDC Exposures: Sources & Routes
As noted above, approximately 1000 chemicals have been identified that meet the criteria of 
an EDC [213, 222]. These compounds are used in a wide range of consumer products 
including food packaging, building materials, pesticides, clothing and upholstery, personal 
care products, detergents and other cleaning agents, thermal paper, plastics and medical 
equipment [210, 215, 227, 228, 256, 257]. Some chemicals used in industrial processes lead 
to unintended contamination of food, water and air. Thus, routes of exposure can include 
oral, dermal, and inhalation, as well as subcutaneous and intravenous (via medical 
equipment).
The US CDC’s National Health and Nutrition Examination Survey (NHANES) is a 
nationally representative biomonitoring program which assesses, among other things, 
exposures to environmental chemicals in the general population [258].The CDC has 
documented widespread exposures to a number of EDCs (e.g. [259-264]). Importantly, a 
large number of chemicals are not examined, and thus the number of exposed individuals, as 
well as the typical levels of exposure, remains unknown. Although the sampling of infants 
and young children is limited in the context of NHANES [265], other studies have revealed 
the presence of environmental chemicals in placenta, amniotic fluid and umbilical cord 
blood, documenting exposure throughout the most critical stages of development as well as 
across the lifespan (e.g. [266-272]).
4.3 Vulnerable Windows of Exposure and Metabolic Disorders
4.3.1 Gestation and neonatal development—The concept that adult diseases could 
have a fetal basis was highlighted by the work of David Barker who proposed a hypothesis, 
which was expanded to the Fetal Basis of Adult Disease and has now been restated as the 
Developmental Origins of Health and Disease (DOHaD) hypothesis [273] [274] [275]. The 
core DOHaD hypothesis is that there are critical windows during development, and 
environmental disruptions during these life stages can lead to subtle changes in gene 
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expression, tissue organization, or other levels of biological organization that lead to 
permanent dysfunction leading to increased susceptibility to disease. Unlike birth defects 
and neonatal diseases, these dysfunctions manifest later in life mostly as increased 
vulnerability to common diseases including obesity [276-278]. Barker and others showed 
that low birth weight (LBW) babies resulting from maternal malnutrition developed 
increased susceptibility to diseases in adult life including coronary heart disease, obesity, 
stroke, T2D, osteoporosis, increased blood pressure, dyslipidemia, impaired glucose 
metabolism and metabolic dysfunction (reviewed in [274, 279].
Barker’s focus on nutrition was preceded by the iatrogenic event involving the prescription 
of diethylstilbestrol (DES) to millions of women from the 1940s through the early 1970s to 
prevent miscarriage. Not only was DES shown to be ineffective, it increased the incidence of 
a rare cervical cancer. Animal studies confirmed it is a transplacental carcinogen and the 
effects, including other deformities of the reproductive tract and increased incidence of 
mammary cancer, shown to result from developmental exposure in animal models, have now 
been confirmed in human studies. The DES tragedy remains one of the best examples of the 
long-latency adverse health outcomes associated with fetal endocrine disruption and was a 
clear example of DOHaD, with adverse health outcomes associated with the alteration of 
normal endocrine function during development [280, 281].
The observation that alternations in human development affects the risk of non-
communicable diseases later in life is confirmed by epidemiology studies focusing on both 
nutrition and environmental chemical exposures [277, 282-284]. Developing organisms are 
extremely sensitive to perturbation by chemicals including EDCs because hormones and 
growth factors control development. Alterations of their levels during development by EDCs 
leads to tissues with abnormal gene expression, numbers of cells, location of cells, 
imbalance between cell types, as well as altered organ structure and hormonal signaling that 
lead to increased susceptibility to disease/dysfunctions across the life course [282, 285]. 
Adverse effects may be most pronounced in the developing organism and occur at 
concentrations of the chemical that are far below levels that would be considered harmful in 
the adult [286, 287]. Some of the reasons for this increased sensitivity include the fact that 
the protective mechanisms that are available to the adult, such as DNA repair mechanisms, a 
competent immune system, detoxifying enzymes, liver metabolism, and the blood/brain 
barrier are not fully functional in the fetus or newborn. In addition, the developing organism 
has an increased metabolic rate as compared to an adult, which, in some cases, may result in 
increased toxicity [287].
Another critically important reason for the increased sensitivity of the developmental period 
to EDCs (as well as nutritional deficits) is that epigenetic signaling regulates gene 
expression which controls development. Epigenetic changes provide biochemical evidence 
of the deleterious effects of adverse conditions during development and subsequent disease 
including metabolic diseases [288]. Some aspects of epigenetic signaling (e.g.DNA 
methylation, histone marks, chromatin remodeling and noncoding RNAs) are likely involved 
in the mechanisms responsible for altered programming of tissue development by EDCs that 
lead to obesity [289-291]. Since hormones and growth factors control development, 
signaling errors caused by hormones expressed at the wrong time or concentration can cause 
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alterations in gene expression in tissues, and these abnormal expression patterns become 
permanent due to epigenetic signaling [291-293].
There are now credible data that supporting the claim that many chronic diseases including 
obesity, T2D and MetS can be linked to epigenetic changes in cells and tissues during 
development that manifest in altered tissue development as a result of early environmental 
factors ( stress, drugs, nutrition, environmental chemicals) [294-296]. Extensive data from 
animal and human studies show that developmentally induced disease outcomes often are 
not immediately apparent but manifest later in life [278, 297, 298].
There are now data that show that environmental factors can account for disruption of 
individual or multiple systems involved in metabolism depending on the timing of exposure. 
For example, exposure to a chemical during the fetal or perinatal period can permanently 
alter the functioning of mesenchymal stem cells and lead to disruption of adipocyte function 
[299]. Altered adipocyte function is likely to affect other organs/tissues due to hormonal and 
paracrine action. This brief chemical exposure might also impact differentiation of the 
pancreas, heart, brain, liver or any other component of the complex regulatory system 
impacting the various components of metabolic disease [276].
4.4 Obesogen Hypothesis Overview (historical)
In 2002, Baille-Hamilton wrote the first article relating environmental chemicals to obesity. 
Her article, “Chemical toxins: a hypothesis to explain the global obesity epidemic”, 
suggested that the current obesity epidemic was associated with the increase in production of 
environmental chemicals [300]. She reviewed published studies showing associations 
between exposure to a variety of environmental chemicals, including some pesticides, 
solvents, plastics, flame retardants and heavy metals, and increased weight gain; because 
these studies originally focused on weight loss and toxicity, their effects on weight gain had 
gone unnoticed. In 2006, Grun and Blumberg, published their now classic paper, in which 
they coined the term “obesogen” followed by a 2009 review “Endocrine disruptors as 
obesogens” [301]. They noted the existence of chemicals that alter regulation of energy 
balance to favor weight gain and obesity and proposed that obesogens derail the homeostatic 
and reward mechanisms important for weight control, such that exposed individuals have 
increased susceptibility to weight gain despite normal diet and exercise.
The obesogen hypothesis makes two important points. First, susceptibility to obesity starts 
during development (in utero and the first few years of life). Second, susceptibility to obesity 
is due in part to the influence of a specific subclass of EDCs that alter developmental 
programming, and thus disrupt the set point for weight gain later in life.
"Obesogens" are defined functionally as chemicals that promote obesity by increasing the 
number of fat cells and/or the storage of fat in existing adipocytes. Obesogens can also act 
indirectly to promote obesity by shifting energy balance to favor calorie storage, by altering 
basal metabolic rate, by altering gut microbiota to promote food storage [302], and by 
altering hormonal control of appetite and satiety [303-307]. New obesogenic chemicals are 
being identified at an increasing rate. The obesogen field has recently expanded to include 
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chemicals that cause or lead to diabetes [308] as well as altered lipid metabolism and fatty 
liver [309].
4.5 The Metabolism Disrupting Chemical (MDC) Hypothesis
In 2015 the Parma Consensus Statement proposed that the Obesogen hypothesis should be 
expanded, considering newer evidence of chemicals that increased susceptibility to T2D, 
liver lipid abnormalities and MetS [310]. The Parma Statement proposed a name change to 
‘metabolic disruptor hypothesis’, which we further propose should be termed ‘metabolism 
disrupting chemical (MDC) hypothesis’ to distinguish the role of chemicals from other 
metabolic disruptors such as nutrition and stress. The MDC hypothesis postulates that 
environmental chemicals have the ability to promote metabolic changes that can result in 
obesity, T2D or fatty liver in animals including humans; these metabolic alterations may 
play an important role in the global epidemics of obesity, T2D and MetS. In the study of 
liver disease etiology, the MDC hypothesis provides, for the first time, a framework for the 
integration of different etiology of steatohepatitis (ASH, CASH, NASH, and TASH). 
Alcohol, chemotherapeutic medications, fructose, dietary fatty acids, and industrial 
chemicals are all MDCs; while they disrupt hepatic metabolism differently the pathologic 
end result is the same [162, 163].
For the remainder of this manuscript we will focus on MDCs as chemicals that can alter any 
aspect of metabolism and describe the current state of the science.
5. MDCs and Metabolism-Relevant Diseases
5.1 Adipogenesis, Subsequent Weight Gain and Obesity
A number of MDCs have been shown to significantly alter the function (gene expression, 
hormone secretion) of white adipose tissue, adipose tissue mass (adipocyte number and/or 
volume), or body weight in animal models after developmental exposures (Figure 2). 
Epidemiological studies also support the identification of obesogenic MDCs [311, 312] and 
these studies focus mainly on weight gain and (body mass index) BMI as endpoints. This is 
typical for a new field, where the focus is on descriptive studies that show that a chemical 
can have an effect on an endpoint or disease of interest (e.g. weight gain). In many cases, 
effects of MDCs on adult adiposity and/or body weight are reported to be significant for 
only one sex, consistent with the sexually dimorphic responses that are a common feature of 
EDCs and thus MDCs [227].
Nicotine is an MDC where there are compelling data for its obesogenic properties from both 
animals and human studies [7, 313, 314]. Maternal smoking in pregnancy is a risk factor for 
subsequent obesity in offspring [315] even when exposure is limited only to early pregnancy 
[316, 317]. Although multiple mechanisms have been proposed, associations may be partly 
attributable to impaired fetal growth, which as Barker and colleagues noted is a risk factor 
for subsequent rapid growth and long-term obesity [318].
Developmental exposure in mice to DES [319] has also been shown to increase weight gain 
which is specific to females and does not appear until puberty [320]. In another study, 
prenatal exposure to DES resulted in an increase in number of adipocytes in the gonadal fat 
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pad of male mice[321]. Two epidemiological studies also link DES exposure to obesity; 
prenatal exposure to DES is associated with an increased likelihood of childhood obesity at 
age 7y [322] and increased risk of adult obesity in women that was most evident at lower 
doses [323].
Bisphenol A (BPA) [324-326], a chemical used to make polycarbonate plastic, epoxy resins 
that line food and beverage cans, and as a developer in cash register receipts has been shown 
to increase weight gain and body fat after developmental exposure in rats [327-329] and 
mice [321, 330-332]. Some studies have not shown effects of BPA on weight gain [333, 334] 
including government standardized study designs e.g. guideline studies, [335, 336]. The two 
guideline studies with CD-SD rats,which appear to be relatively insensitive to xenoestrogens 
[337], showed no significant effects for any outcome measure. Also in one mouse study 
reporting no significant effect of BPA on body fat[333], the control animals were obese due 
to the use of casein-based feed, which increases body fat in CD-1 mice [338, 339] . These 
studies differ with regard to several aspects including animal strain, doses, developmental 
windows, and diet which are likely responsible for the discordant results (reviewed in [340]). 
Also a distinction needs to be made between studies that only measured body weight (for 
example [331] ) which is recognized to be a poor indicator of significant changes in body fat 
in rodents [7] and studies that actually measured body fat.
Human studies have shown that prenatal exposure to BPA was associated with increased 
body fat at age 7 [341] or BMI by age 9 [342] or accelerated postnatal growth without a 
change in BMI between age 2-5 [343] consistent with the DOHaD prediction that light at 
birth babies would experience increased rate of growth in childhood[14, 344]. Not all 
epidemiology studies report a positive relationship between an exposure and a health 
outcome [342, 343, 345-347] which is not uncommon for studies linking environmental 
chemicals with adverse outcomes in humans, possibly due to potential for multiple 
environmental “stressors” to interact with chemical exposures [345, 348, 349]. Because of 
considerable within-person variability [350-353] and because most studies typically have 
only one sample to characterize exposure, BPA exposures may have been substantially 
misclassified and peak exposures, which generally occur in the evening, may have been 
underestimated [351]; these misclassifications may have increased the likelihood of a false 
negative outcome. Stronger attention is also needed for potential confounding by diet, which 
is only one source of BPA exposure [257, 354]. Moreover, since the developing organism is 
more susceptible to BPA effects, epidemiology studies must consider the lifestage when 
exposure is measured. The inconsistencies in the data notwithstanding, there are data from 
both animal and human studies that support the hypothesis that developmental exposure to 
BPA can lead to an increase in weight gain later in life in exposed offspring.
Phthalates are a class of chemicals that promote flexibility in plastic products such as tubing 
and vinyl flooring. Fragrances and a variety of household and personal care products 
including food packaging also contain a variety of phthalates. Phthalate metabolites have 
been shown to activate PPAR receptors and have antiandrogenic effects which may 
contribute to the development of obesity [355]. Prenatal exposure of mice to one phthalate, 
DEHP, results in increased body weight as well as increased body fat in male offspring; 
similar findings were reported in studies from different labs using different animal models 
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[356-359]. Epidemiologic data linking prenatal phthalate exposures to obesity are limited 
and mixed [360-364]. Although daily exposure measurements are less variable than BPA, 
phthalates are also prone to exposure misclassifications. One recent study found evidence of 
a sex-specific effect, with high molecular weight phthalates — including DEHP — 
associated with reduced BMI z-scores among boys, but increased BMI z-scores among girls 
from Spain [362]. DEHP metabolites were associated with lower BMI z-scores in ethnically 
diverse boys from a US cohort [360], and in children of both sexes in another [361]. 
However, high molecular weight phthalates were associated with higher BMI z-scores in US 
children of Mexican American and African American descent, though not in Whites [365]. 
Phthalate exposure during pregnancy was also associated with increased triglyceride levels 
in cord blood and with increased body mass three months after birth in boys [366]. While 
more data are needed, these data support the conclusion that developmental exposure to 
DEHP and perhaps other phthalates, depending on their molecular weight, can lead to 
increased weight gain in animal and human studies.
Tributyltin (TBT) [367, 368] is an organotin used as a fungicide; it is a retinoic acid X 
receptor and PPARγ agonist. Several laboratories have shown that TBT stimulates 
adipogenesis in preadipoctyes in vitro [369-371] [372]. Prenatal exposure to TBT results in 
increased lipid accumulation, increased adipose tissue mass (due to both adipocyte 
hyperplasia and hypertrophy), and reduced muscle mass that persists into adulthood and 
across generations in mouse models [309, 367] and increased adiposity in zebrafish [373]. A 
recent study explored organotins and weight gain in humans for the first time, finding 
placental TBT to be associated with a non-significant trend towards higher weight gain, but 
only in the first three months of life [374]. These limited data in humans warrant further 
investigation, whereas the animal data strongly support the notion that TBT exposure during 
development may play a role in the obesity epidemic.
Polycyclic aromatic hydrocarbons (PAHs) are a family of environmental chemicals that are 
byproducts of fossil fuel burning which includes diesel exhaust, air pollution and cigarette 
smoke [206]. Prenatal exposure to a nebulized PAH mixture 5 days a week for three weeks 
led to increased weight, fat mass and higher gene expression of PPARγ, fatty acid synthase 
and adiponectin in mice[375]. Developmental exposure in rats to PAHs in diesel exhaust 
have been shown to lead to increased obesity, insulin resistance and inflammation; these 
effects were observed only in adults fed a high fat diet, indicating a second hit was needed, 
and only in males, indicating a sexually dimorphic effect [376, 377]. Specific exposure to 
benzo (a) pyrene during development also resulted in increased visceral adipose tissue 
weight in female offspring [378].The use of different model systems and exposures limits 
our ability to determine the importance of PAHs as an important contributor to obesity. 
There are limited human data on the association of childhood obesity with maternal 
exposure to ambient PAHs, however a study by Rundle and colleagues [379] shows children 
born to mothers with the highest PAH exposures during pregnancy had higher body weights 
both at 5 and 7 years of age. The extensive exposure of populations to air pollution 
necessitates a further examination of its overall effects and its specific contribution to 
increased risk of obesity.
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The most consistent human evidence that prenatal MDC exposure is associated with obesity 
in offspring is for several organochlorine compounds: the in vivo metabolites of DDT 
(DDE), as well as hexachlorobenzene (HCB) [311, 312, 380, 381]. Persistent organic 
pollutants (POPs) are a class of chemicals that bioaccumulate in tissues and magnify in the 
food chain [382]. They include some pesticides (DDT, HCB) and some industrial chemicals 
such as polychlorinated biphenols (PCBs). While the use of these chemicals is banned in 
many countries (PCBs, HCB and DDT) exposures exist due to their persistence in the 
environment. In some countries like South Africa DDT is still used thus current exposure 
also exists. Exposure during early gestation to some POPs, namely PCBs, HCB and DDT, 
can lead to the development of obesity later in life [383] [312, 381, 384-388]. In rodent 
studies, prenatal exposure to DDT followed by a high fat diet for 12 weeks in adulthood led 
to the development of glucose intolerance, hyperinsulinemia, dyslipidemia and altered bile 
acid metabolism as well as reduced energy expenditure and impaired thermogenesis as 
measured by reductions in core temperature in female offspring [389]. Six separate 
epidemiology studies showed that prenatal DDE exposures were associated with increased 
BMI in the offspring at ages 1 and 3 [390], at age 4 [381] and between ages 5-7[384] [384], 
as well as increased overweight at age 6.5 [386], 7 years [380], and age 9 [391]. Prenatal 
exposure to HCB has been associated with rapid growth in the first 6 months of life and 
obesity in infancy and childhood [383, 392]. Similarly, prenatal exposure to specific PCB 
congeners resulted in increased BMI at 14 months [387], at 1 and 3 yrs. of age [390], and 
age 5 and 7 [393].
Effects of several POPs on growth may be sex-specific. For example, some associations 
between PCBs and measures of general or central obesity are specific to girls [384, 386, 
394] while the weight gain due to DDT/DDE occurred in boys or girls depending on the 
cohort and conditions of the study. In addition, it remains uncertain to what extent the effects 
of these chemicals on long-term growth may be due to indirect effects, dependent on the 
mismatch between a prenatal environment that can program offspring to survive in an 
environment that inhibits growth and the energy-dense diets available in the postnatal 
environment. Many POPs for which prenatal exposure is associated with obesity are also 
associated with smaller size at birth [385], and thus associations with obesity may be, at 
least in part, related to rapid postnatal growth in these children, similar to that observed in 
offspring of smokers and malnourished infants [316, 387, 388, 395]. In contrast to the 
human data, there is a paucity of animal data on the role of POPs on obesity; this area 
requires future study.
Data are limited, and sometimes inconsistent, for associations between obesity and a number 
of chemicals in humans [312] and animals [206]. For example, prenatal exposure to 
perfluorinated compounds, chemicals used to repel grease stains in carpets and clothing, was 
not associated with subsequent adiposity in childhood [396] in a recent study, though a prior 
study found such an association at age 20y [397]. Similarly, in animal models, one study 
found in utero exposure to perfluorooctanoic acid (PFOA) led to weight gain in offspring in 
outbred CD-1 mice [398] whereas another inbred transgenic mouse model did not show any 
weight gain [399]. The animal [400] and epidemiological data on obesogenic effects of 
prenatal exposure to arsenic [401, 402] while limited are consistent across species. Cd, Pb 
and As exposures are associated with smaller size at birth [403-406] which is a risk factor 
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for subsequent weight gain and greater adiposity. Prenatal exposure to toxic metals is also 
related to higher leptin at birth [407, 408]. Similarly, limited but consistent data suggest 
obesity-related effects of exposures to various flame retardants in utero in humans with some 
indication of sex-specific effects [409]. Developmental exposure of rats to Firemaster 550, a 
flame retardant mixture, was associated with weight gain later in life [410].
Taken together, these observations support the relevance of the MDC hypothesis with respect 
to weight gain in animal and human studies.
5.2 MDCs and Fat Cell Differentiation and Development
Preadipocytes such as 3T3-L1 cells are often used as models to test the ability of chemicals 
to induce adipogenesis. A recent study used 3T3-L1 cells and MSCs to evaluate the effects 
of a collection of chemicals on adipogenesis and adipogenic gene expression [411]. This 
study found that several pesticides with different chemical structures and modes of action, 
zoxamide, spirodiclofen, quinoxyfen, fludioxonil, tebupirimfos, forchlorfenuron, flusilazole, 
acetamaprid, and pymetrozine all induced adipogenesis and adipogenic gene expression in 
3T3-L1 preadipocytes, whereas quinoxyfen and fludioxonil were also able to induce 
adipogenesis and adipogenic gene expression in MSCs [411, 412] (Figure 2). Dioxins and 
PCBs acting via the AhR alter the expression of important genes related to adipogenesis, 
lipid metabolism and inflammatory factors [413-417]. Activation of PPARγ via exogenous 
ligands such as rosiglitazone or TBT strongly promotes adipocyte differentiation and 
maintenance, together with the expression of genes involved in lipid droplet formation, 
glucose uptake, fatty acid synthesis, and adipokine secretion [418] [419]. Other studies have 
identified BPA [132, 420, 421], bisphenol A diglycidyl ether [422], aklylphenols [423], 
phthalates [356, 357, 372, 424, 425] and flame retardants [372, 424, 426, 427] as well as 
organochlorine [428, 429] and neonicotinoid pesticides [430] as chemicals that can promote 
adipocyte differentiation.
In addition to differentiation of cell lines to adipocytes, it is also possible to regulate the fate 
of MSC to result in increased numbers of fat cells. Because multiple signaling pathways 
converge to regulate MSC fate, there are numerous opportunities for extrinsic factors to 
disrupt or modify differentiation. For example, the pesticides chlorpyrifos and carbofuran 
inhibited the ability of MSCs to differentiate into bone [431] although the potential to 
differentiate into fat was not tested. Treatment with the organotin TBT or the pharmaceutical 
rosiglitazone (ROSI) led to adipogenic differentiation of 3T3-L1 preadipocytes and MSCs in 
vitro [432, 433] in a PPARγ-dependent manner [434]. The fungicides triflumizole [357] and 
tolyfluanid [434] also promoted adipocyte differentiation and gene expression in MSCs and 
3T3-L1 cells. Prenatal exposure of pregnant mice to TBT or ROSI led to increased fat 
deposition at birth [367]. These exposures also diverted MSCs toward the adipogenic lineage 
at the expense of the osteogenic lineage [432]. Although adipogenesis and obesity have been 
the most studied outcome of exposure to obesogens and MDCs, it should be obvious that the 
bipotential switch between the adiopogenic and osteogenic lineages opens an entirely new 
field for the effects of MDCs on bone development and osteoporosis.
It is clear that chemicals can alter MSC lineage allocation in animal models; however, there 
are no studies that examine MSC lineage commitment in obese verses lean individuals. 
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Nonetheless, it is worth focusing on the potential consequences of chemicals altering MSC 
lineage in humans. Obese individuals definitely have more fat cells than individuals of 
normal weight [106]. It is likely that obese individuals either were born with more fat cells 
because of prenatal programming or developed them early in life by mechanisms outlined 
above. It is probable that adipogenic stimuli (such as exposure to chemical obesogens or 
inappropriate diet) received perinatally or during adolescence permanently increased fat cell 
number. In turn, this creates an altered metabolic set-point that favors the storage of calories 
as fat. Once fat cell number is programmed, the number cannot be altered readily by diet, 
exercise, or even surgery [106]; many studies have documented the expansion of visceral fat 
depots in adults via increased adipocyte number [107, 435, 436] whereas permanent 
decreases in cell number accompanied by weight loss have not been documented. It is 
possible to successfully shrink the size of existing fat cells by faithful adherence to a 
restrictive diet and a vigorous exercise regimen. However, clinical studies repeatedly show 
that 83-87% of people who achieve significant weight loss regain the weight within a few 
years [437, 438]. These data strongly suggest that obese individuals have altered metabolic 
set-points that favor calorie storage over the long term.
There is no evidence that lipid-depleted fat cells automatically undergo apoptosis. Indeed, it 
is difficult to envision how such a scenario would be favored over evolutionary time since 
healthy fat cells would be required for the organism to survive periods of fasting that 
regularly occur in hunter-gatherer societies. Moreover, expression of the satiety hormone, 
leptin closely parallels fat mass and small fat cells secrete the least leptin making it likely 
that shrunken fat cells would "crave to be filled” [439].
5.3 MDCs and Neuroendocrine Control of Feeding and Metabolism
Only a few studies have investigated the action of potential MDCs on neural circuits/cells 
and on the resulting feeding behavior and energy balance output. However, the 
neuroendocrine control of these features could be an important target of environmental 
chemicals.
Prenatal exposure to low doses of BPA alters the development of the POMC system in a 
sexually differentiated way [440]. The differences are evident when adult are exposed to a 
high-fat diet; in particular, males show reduced POMC fiber innervation of the PVN and 
increased NPY and AGRP expression in the ARC. Females exposed to BPA show reduced 
POMC expression and ERα expression patterns in the ARC similar to those seen in males, 
suggesting a masculinizing effect of BPA. Also, fetal exposure to BPA in mice alters food 
intake during puberty and in adulthood as well as leptin and insulin levels, which in turn 
regulate the NPY system[321].
Organotin compounds such as TBT have not only peripheral effects, but also may activate 
elements in the brain, in particular in a crucial region for the regulation of food intake, the 
ARC [441] . Adult mice exposed to TBT for 4 weeks show profound alterations of the 
leptin-NPY-NPY-Y1 receptor system [96, 188]. Prenatal exposure to TBT also induces 
hypothyroidism in the progeny, while the acute treatment of pregnant females induces a 
dose-dependent increase of T3-independent TRH transcription levels [442] in the 
hypothalamus.
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In summary, there are a number of important endpoints to study the effects of MDCs on the 
regulation of food intake and metabolism in the central nervous system. These include 
expression of the leptin receptor, ERα, thyroid hormone receptor (associated also with 
PPARy), the POMC-CART system, the NPY-AGRP system and their receptor systems, and 
the dopaminergic system.
5.4 Sexually dimorphic effects
Because by definition they interfere with hormonal actions, sex specific effects are expected 
for many MDCs. A critical aspect regarding research on sex differences related to metabolic 
disease is that until recently, the majority of biomedical studies have focused only on males. 
With regard to the impact of MDCs on adipocity and metabolism, it is well known that 
females differ dramatically from males in subcutaneous fat deposition as well as in the 
endocrine function of adipocytes. For example, females have higher circulating 
concentrations of both leptin and adiponectin relative to males {Mauvais-Jarvis, 2015 
#2079} Thus, while not all studies that examined a few outcomes of exposure in males and 
females report sex differences, one would expect on detailed examination to find sex 
differences. In this regard, some studies have demonstrated that MDCs can masculinize or 
feminize energy balancing traits depending upon type and dose of the tested chemical, the 
timing of exposure and the metabolic challenge. In experimental animals, sex-dependent 
differences in body weight in response to prenatal or early postnatal exposure to low doses 
of BPA or DES have been reported; both chemicals increased body weight in female rodents 
but decreased or did not affect it in males [328, 443]. A recent study has examined in detail 
the energy balance traits of mice prenatally exposed either to a low or a high dose of BPA or 
to DES showing that exposure to BPA but not to DES hypermasculinized male and 
masculinized female mice (see also [440]). In addition, exposure to MDCs can diminish, 
eliminate, reverse or widen sex differences in behavior, thus interfering with normal sexual 
differentiation of the brain [444-447] which can also affect metabolic processes. For 
example, numerous studies have confirmed the ability of BPA to affect the rodent 
developing brain in a sex-specific manner (for review see [448] even at very low doses [449, 
450], indicating that the brain is a very sensitive target organ for BPA action. The cerebral 
cortex, hippocampus and hypothalamus are key sexually dimorphic regions in the rodent 
brain, and these brain areas can be affected by pre- and perinatal MDC exposure, with sex 
specific effects observable even before the increase in gonadal hormones during puberty. 
The developing hypothalamus has sex-specific vulnerability to BPA, with the preoptic area 
(POA) and mediobasal hypothalamus (MBH) being the most studied and robustly affected 
[97, 451].
5.5 Type 2 Diabetes (T2D)
Evidence that chemicals can disrupt the function of the endocrine pancreas dates to the early 
1940s when alloxan, a glucose analogue which selectively destroys insulin producing cells 
in the pancreas, was shown to promote type 1 diabetes in rabbits [452]. This was followed 
by the discovery that streptozotocin similarly induced a diabetic state through selective β-
cell destruction. Although humans are not exposed to alloxan or sreptozotocin, they are used 
in animal research on diabetes. Initial human evidence that synthetic chemicals promote the 
development of diabetes came from patients accidentally or intentionally exposed to 
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pyrinuron (Vacor) [453]. Exposure to this rodenticide resulted in β-cell destruction and the 
development of type 1 diabetes [454]. More recently, a patient exposed to high levels of the 
fungicide chlorothalonil was reported to develop diabetic ketoacidosis, a condition arising 
from insulin deficiency [455]. These and other studies of environmental contaminants 
provide mechanistic insights into the pathways by which MDCs may promote diabetes 
pathogenesis through defects in β-cell physiology.
5.5.1 MDCs and Beta Cell Survival and Function
5.5.1.1 Cellular Studies: A structurally diverse array of synthetic and inorganic toxicants 
disrupts β-cell survival and function in cell lines and isolated rodent islets. 2,3,7,8-
tetrachlorodibenzodioxin (TCDD) reduces glucose-stimulated insulin secretion (GSIS) in 
isolated islets [415, 456, 457]. Similarly, DDT impairs both GSIS as well as insulin 
secretion in response to tolbutamide (a pharmacological insulin secretagogue) [458]. Among 
organotin compounds, triphenyltin was shown to disrupt cellular signaling in β-cells and 
impair insulin secretion in response to a variety of stimuli [459]. Similarly, inorganic 
contaminants including both inorganic and methylated arsenic [460-462], cadmium 
[463-465], and mercury [466] disrupt β-cell function (Figure 2).
Interestingly, several compounds disrupt β-cell signaling and function in a manner that 
promotes insulin release. In the RINm5F cell line, a PCB mixture (Aroclor 1254) increased 
insulin secretion into the culture media, an effect recapitulated by coplanar PCB congeners 
[467]; TCDD also promotes continuous insulin release [468]. Interestingly, the insulin 
secretory effect resulted in a depletion of cellular insulin content by PCBs [467] and TCDD 
was proposed to promote β-cell “exhaustion” [468]. This suggests that prolonged exposure 
to these compounds could result in insulin deficiency.
BPA has been shown to augment GSIS; unlike TCDD and PCBs, low doses of BPA 
augmented β-cell insulin content in an ERα dependent manner [469]. A rapid action on 
insulin release was shown to be dependent on ERβ expression, and was confirmed in human 
as well as mouse islets [470, 471]. Importantly, these effects of BPA may be representative 
of effects of other phenolic compounds because nonylphenol and octylphenol were also 
shown to augment GSIS in isolated rat islets [472].
In contrast to the extensive work examining MDC effects on β-cell physiology, less is 
known about the effects of environmental pollutants on α-cell biology. In early studies, 
cobalt was shown to be toxic to α-cells [473]. More recently, BPA has been shown to alter 
calcium signaling in α-cells [474]. Collectively, these data support the theory that the 
endocrine pancreas is an important target for the deleterious effects of MDCs on energy 
homeostasis.
5.5.1.2 Animal studies: Exposures During Adulthood: The strength of evidence 
supporting environmental toxicants altering β-cell physiology is reinforced by animal 
studies that examine the effects of whole-body exposure to a variety of MDCs on insulin 
secretion and glucose homeostasis. Although the focus of this review is on developmental 
exposure, in the case of MDCs exposures and T2D, it is important to also mention adult 
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studies. These studies demonstrate a direct induction of insulin resistance without the need 
for an increase in weight or adiposity.
Adult mice exposed to TCDD exhibited reduced glucose-stimulated insulin release without 
concomitant hyperglycemia, an effect that was absent in AhR-null mice [456]. Furthermore, 
TCDD-exposed rats had islets depleted of insulin [415], similar to the depletion of secretory 
granules observed with chronic exposure to PCBs [475]. This contrasts with the effects of in 
vivo BPA exposure, which augments insulin release and increases β-cell insulin content in a 
murine model [469]. Oral administration of TBT was shown to promote hyperglycemia with 
reduced circulating insulin levels accompanied by increased islet apoptosis and reduced 
cellular proliferation, suggesting a β-cell defect as a contributing lesion to TBT-induced 
metabolic dysfunction [476].
The use of genetic models of type 1 and T2D have also unlocked the deleterious effects of 
MDCs on β-cell biology. In the db/db mouse model of T2D in which a defect in the leptin 
receptor promotes the development of obesity and diabetes, exposure to arsenic through 
drinking water enhanced the development of hyperglycemia with concomitant reductions in 
insulin levels, suggesting an arsenic-induced impairment in β-cell function [477]. The non-
obese diabetic (NOD) mouse, in contrast, is a model of type 1 diabetes as these mice 
develop autoimmune inflammation of the pancreatic islets (insulitis) and insulinopenic 
diabetes. Chronic exposure to BPA modulates insulitis in female NOD mice with complex 
concentration-dependent effects [478].
5.5.1.3 Epidemiological studies in adult human populations: The effects of MDCs on β-
cell physiology in adult human studies are limited. In a Northern Mexican cohort, inorganic 
arsenic exposure was associated with a reduction in β-cell function, with the effect amplified 
among those with T2D [479]. Along with larger epidemiologic literature linking arsenic 
exposure to diabetes [480-482], other studies have also found arsenic to be associated 
specifically with measures of β-cell dysfunction or reduced insulin secretion, more strongly 
than with measures of insulin resistance [483, 484]. Epidemiological studies also suggest 
that BPA, phthalates, dioxins, and POPs including DDT metabolites and PCBs are 
associated with measures of altered glucose homeostasis including T2D [345, 485-489]. In 
one recent study, urinary BPA concentration in US adults was associated with an increase in 
β-cell function, hyperinsulinemia and insulin resistance [490] preferentially in males. These 
results are similar to those obtained from studies performed in mice [469].
Consistent with animal studies [491], a number of human studies —including studies among 
children and numerous studies in adults— suggest that DEHP is more strongly associated 
than are other phthalates with diabetes and other markers of impaired glucose metabolism 
[365, 492-495], perhaps because of greater activation of PPARs. However, several other 
studies [496-498] found stronger evidence of associations with butyl phthalates, which have 
a weaker PPARγ affinity than do DEHP metabolites [499]. Because data thus far are limited, 
it is uncertain to what extent the mixed results in humans may be due to factors such as 
differences in exposures [496], measurement errors in estimates of exposure [350], or sex-
specific effects [500]. Moreover, to date very few epidemiological studies have examined the 
developmental or perinatal exposures thought to have the most potent diabetogenic effects 
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[501], though recent animal studies support adverse effects of ongoing exposures including 
those in adulthood [502, 503]. Nonetheless, overall, these studies support the idea that 
MDC-induced disruptions in β-cell function may mediate some of the observed associations 
between environmental chemicals and diabetes in human populations.
5.5.1.4 Animal studies: Gestational and Perinatal Exposures: While disruptions in 
glucose homeostasis due to diminished insulin action result from developmental exposure to 
several chemicals, evidence specifically linking MDCs to impaired β-cell function is less 
common(Figure 3). In a rat model, females exposed to the phthalate DEHP throughout 
gestation and perinatal development exhibited hyperglycemia in the presence of reduced 
insulin levels [504]. Histological evaluation of pancreatic islets from weanlings revealed 
reductions in β-cell mass, reduced islet insulin content, and disruptions in β-cell 
ultrastructure [491]. In a similar model, restriction of exposure to days 9-21 of gestation, 
albeit to higher DEHP levels, similarly altered β-cell function and reduced insulin levels 
with hyperglycemia [505].
In the NOD model of type 1 diabetes, in utero and perinatal exposure to BPA increased the 
severity of insulitis at 11 weeks of age and increased the prevalence of diabetes at 20 weeks 
of age in female mice [506]. Interestingly, a recent study also demonstrated that BPA 
exposure during pregnancy promotes the development of glucose intolerance in later life 
through impairments in β-cell function and mass [507]. This suggests that exposures during 
pregnancy may alter the long-term metabolic trajectory of both the mother and her offspring. 
These studies support extending the view of ‘developmental windows’ beyond early life, as 
important periods of sensitivity to disruptions in β-cell function may be mediated by 
exposure to environmental toxicants during other critical periods, e.g. pregnancy.
Collectively, experimental evidence from cell lines to humans supports the endocrine 
pancreas as a target for disruption by diverse MDCs. Further work is required to determine 
the exposure conditions under which α- and β-cell physiology is disrupted in humans to 
better characterize the threat of exposures to MDCs to metabolic health.
5.5.2 MDCs, Insulin Action and Glucose Disposal
5.5.2.1 Cellular models: In addition to data demonstrating that MDCs disrupt insulin 
production, an increasing body of evidence suggests that a variety of MDCs have the 
capacity to impair peripheral insulin action. In diverse cell line and organ culture models of 
insulin-responsive tissues, an array of compounds have been shown to impair insulin signal 
transduction or insulin-stimulated glucose disposal, including TCDD [508, 509], tolylfluanid 
[510], inorganic and methylated arsenic species [511, 512], DEHP [513, 514], and POPs 
[416]. In one model, BPA was also shown to inhibit insulin-stimulated glucose utilization in 
3T3-L1 adipocytes [417] and another study showed that BPA can increase basal and insulin-
stimulated glucose uptake in 3T3-F442A cells [412]. BPA also stimulated secretion of pro-
inflammatory cytokines IL-6 and TNF while inhibiting the anti-inflammatory cytokine 
adiponectin from human adipoctyes in culture {Ben-Jonathan, 2009 #2081}. Collectively, 
these data suggest impairments in insulin action may result from exposure to a variety of 
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environmental MDCs; however, dose, duration, and model system may alter the phenotypic 
response of some tissues to these compounds.
5.5.2.2 Adult animal studies: Evidence that MDCs disrupt cellular energy handling is 
supported by data from animal models in which multiple compounds have been shown to 
promote insulin resistance. For example, in vivo exposure to DEHP down-regulates 
expression of adipocyte insulin signaling intermediates [515], while rats exposed to BPA 
demonstrated a reduction of insulin signaling intermediates in both muscle [516] and liver 
[517]. Cadmium exposure has been shown to promote glucose intolerance with a specific 
reduction in adipose expression of Glut4 [518] and TCDD has been shown to also reduce 
glucose uptake in adipose and brain [519, 520]. In addition, the fungicide tolylfluanid 
promotes glucose intolerance with concomitant global and adipose-specific insulin 
resistance, with the latter resulting from a specific down-regulation of insulin receptor 
substrate-1 (IRS-1) [521].
While less specific, a variety of studies have also shown that exposure to various organic and 
inorganic toxicants promotes global insulin resistance or glucose intolerance with associated 
shifts in serum insulin levels. For example, in vivo exposure to inorganic arsenic promotes 
glucose intolerance with concordant insulin resistance [477, 522], including accentuation of 
the inherent insulin resistance of pregnancy [523]. Extended exposure to air pollution 
particular matter (PM2.5) for 24 weeks induced whole body insulin resistance in mice [524]. 
Acute and chronic malathion exposure resulted in increases in both glucose and insulin 
levels in rats [525]. Chronic exposure to POPs has also been shown to promote insulin 
resistance [502]. Similarly, BPA promotes insulin resistance in mice [469], and this effect 
can be observed with exposures as short as 8 days [526]. In addition to effects on β-cells, in 
vivo studies of TBT exposure in mice demonstrate hyperinsulinism [527].
While these studies emphasize the diverse array of compounds that can alter insulin action, 
key factors may modulate the ultimate metabolic phenotype. For example, female mice 
exposed to arsenic develop glucose intolerance; however, the etiology may be influenced by 
the background hormonal status of the animal as ovariectomized mice exhibit elevated 
insulin levels while those with intact ovaries have reduced insulin levels [528]. Furthermore, 
an animal’s genetic background may also influence the phenotype. In one study, inorganic 
arsenic was shown to preferentially induce glucose intolerance in diabetic db/db mice but 
not non-diabetic mice [477]. Importantly, additional metabolic stressors such as high fat 
feeding may also modify MDC effects on energy homeostasis. Atrazine has been shown to 
promote insulin resistance, an effect exacerbated by a high fat diet [529]. BPA also promotes 
glucose intolerance and impair insulin action in a chronic model of exposure coupled with a 
high fat diet [530]. Interestingly, PCB77 and PCB126 were shown to impair glucose 
tolerance with the induction of systemic insulin resistance when coupled with a low fat diet; 
however, the effect of PCB77 on glucose tolerance was absent in the context of high fat diet 
but reemerged with weight loss [531]. Indeed, the evidence for diet-PCB interactions in 
promoting insulin resistance may be quite complex and congener-specific as exposure to the 
PCB mixture Aroclor 1254 induced insulin resistance in both lean and diet-induced obese 
states [532]. Similarly, in one epidemiology study, effects of PCBs on odds of diabetes 
appeared to be modified by intakes of fruits and vegetables [533]. Conversely, rats exposed 
Heindel et al. Page 30
Reprod Toxicol. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
to PM2.5 developed increased insulin levels and elevated HOMA-IR only in the context of a 
high fat diet [534] and Aroclor 1260 administered to mice fed a high fat diet altered 
carbohydrate metabolism at multiple levels including glucose tolerance, insulin resistance/
sensitivity, adipokines, pancreatic insulin secretion, and hepatic gluconeogenesis [535]. 
Taken together, this evidence suggests that the relationships between MDCs and dietary 
metabolic stressors are complex, with an ultimate phenotype that may be exposure-specific.
5.5.2.3 Animal studies: gestational and perinatal exposures: Various models have 
suggested that imbalances in insulin action can arise from MDC exposures during 
development. BPA enhanced the insulin resistance of pregnancy, with female offspring 
demonstrating higher insulin levels and males exhibiting glucose intolerance with systemic 
insulin resistance [536]. Insulin resistance was also observed in BPA-exposed rats [537], 
while another mouse model similarly demonstrated glucose intolerance with insulin 
resistance; however, the effect was observed only at low doses[321]. Metabolic stressors like 
high fat diet may be additive to the BPA-induced insulin resistance [331]. Indeed, high-fat 
diet potentiated GSIS impairments elicited by low doses of BPA given subcutaneously 
[538]. In the CD-1 mouse, however, developmental exposure to BPA did not alter glucose 
homeostasis in adult mice fed a normal chow or high fat diet [333]. Overall, these findings 
suggest that developmental BPA exposure can alter metabolism, albeit the ultimate 
metabolic phenotype may be modulated by genotype, diet and exposure patterns.
Additional studies have suggested that developmental exposure to other compounds can 
promote alterations in insulin action. For example, exposure to low doses of PFOA in 
midlife were shown to increase insulin levels [398], while PFOS exposure during gestation 
and early postnatal development resulted in glucose intolerance and insulin resistance [539]. 
Rats exposed to PFOS from gestation day 0 to postnatal day 21 also shown exhibited 
glucose intolerance with elevated insulin levels [540].
Developmental exposure to DEHP induces a complicated phenotype with the development 
of hyperglycemia with reduced insulin levels in female rats, while male offspring had 
elevated insulin levels but normal glucose tolerance [491]. In another model, DEHP 
exposure led to glucose intolerance with insulin resistance in the offspring, although this 
model also revealed central defects in β-cell function as well [505]. Sex-specific effects of 
DEHP on measures of insulin resistance have been reported in some epidemiological studies 
[495], but not others [541].
These data suggests that both adult and developmental exposures to various MDCs have the 
capacity to modulate insulin action globally as well as at the cellular level. This conclusion 
is further supported by a number of studies, not discussed, in which MDC exposure 
promoted glucose intolerance without examination of insulin levels or action. However, the 
precise mechanism(s) by which this common phenotype occurs remains somewhat obscure. 
Examining the totality of the data, several molecular pathways are implicated as potential 
mechanisms of altered insulin action. These include increased production of 
proinflammatory cytokines that induce insulin resistance such as TNFα and IL-6 [508, 524, 
542], increased oxidative stress [466, 477, 515, 525, 543], and mitochondrial dysfunction 
[529], which may also increase oxidative damage. Further work is required to fully 
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characterize the modes by which MDCs promote impaired insulin action to devise strategies 
to mitigate their adverse effects on global energy homeostasis.
5.5.3 MDCs and Energy Homeostasis—In addition to the effects of MDCs on insulin 
production and action, specific defects in intermediary metabolism have also been described 
for MDCs using a variety of model systems. For example, in the 3T3-F442a cell line, TCDD 
reduces expression of lipoprotein lipase [509], suggesting one mechanism by which MDCs 
may promote hypertriglyceridemia. PBDE exposure inhibits adipose glucose oxidation while 
augmenting isoproterenol-induced lipolysis [544], potentially increasing circulating free 
fatty acid levels, which are substrates for hepatic triglyceride synthesis.
Additional lipid abnormalities may be induced by perinatal exposure to 4-nonylphenol 
which has been shown to increase serum total cholesterol [423]. Disruptions in hepatic 
metabolic function were shown with subchronic exposure to malathion, which induced 
hyperglycemia with evidence of increased hepatic gluconeogenesis and glycogenolysis 
[545]. Chronic intake of DEHP impairs glucose tolerance with an alteration in glycolytic 
intermediates in both liver and muscle that were suggestive of impaired lactate as well as 
glucose handling [546]. In utero and lactational exposure to BPA in a rat model 
demonstrated a reduction in hepatic glycogen content at 21 weeks of age with evidence that 
the promoter for hepatic glucokinase was hypermethylated, suggesting a reduction in the 
expression of this key enzyme [537]. In a multigenerational rat model, BPA exposure in the 
F0 generation promoted glucose intolerance and insulin resistance in the F2 generation with 
an associated reduction in hepatic glucokinase expression and concomitant 
hypermethylation of the gene promoter [547]. Interestingly, adult mice exposed to BPA have 
also been shown to exhibit reduced hepatic glucokinase activity [548]. This suggests that 
disruptions in hepatic glucose handling may be a common mode by which MDCs promote 
metabolic dysfunction.
5.6 MDCs, Hepatic Steatosis, and Hyperlipidemia
Developmental studies examining MDCs and liver health endpoints have been conducted in 
laboratory animals, but epidemiology studies examining the developmental basis of these 
diseases are lacking. This is likely due to the relatively long time to develop clinically 
apparent human liver disease owing to the slowly progressive nature of hepatic fibrosis. 
Compounding the problem, routine clinical biomarkers (e.g. alanine aminotransferase) may 
be insensitive for the detection of environmental liver disease[549] Novel biomarkers for 
fatty liver disease and fibrosis [550] are being developed for clinical use, and perhaps these 
could be applied to future environmental epidemiology studies. Due to the relative lack of 
epidemiological data on developmental MDC exposures in steatosis and hyperlipidemia, 
post-developmental studies (adolescent and adult) provide ‘proof of concept’ and thus are 
reviewed below.
5.6.1 Adult MDC Exposures, Steatosis and Hyperlipidemia—Hepatic steatosis is 
likely to be the most common pathologic liver responses to chemical exposures [163]. 
Indeed, hepatic steatosis was noted in approximately 8-10% of rodent studies warehoused in 
the Environmental Protection Agency’s (EPA) Integrated Risk Information System (IRIS) 
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database and the Toxicological Reference Database (pesticide) [162, 551]. Furthermore, in 
the Chemical Effects in Biological Systems (CEBS) data repository of the US National 
Toxicology Program (NTP), 329 rodent studies of 81 unique chemicals reported hepatic 
steatosis [551]. Whatever its etiology, hepatic steatosis is invariably associated with insulin 
resistance [163]. However, this interaction is complex as fatty liver disease is both a cause 
and effect of insulin resistance.
While some chemicals (e.g. vinyl chloride) appear to directly cause steatosis and 
steatohepatitis [552], other chemicals such as non-dioxin like PCBs merely modify the 
hepatic response to diet-induced obesity [535]. These chemicals may be a ‘second hit’ in the 
progression of diet-induced steatosis to frank steatohepatitis, which may further progress to 
cirrhosis and hepatocellular carcinoma. Many non-dioxin like PCBs interact with NR1 class 
nuclear receptors such as PXR and CAR [553]. However, the role of MDC-nuclear receptor 
interactions in fatty liver disease is likely to be complex, as PPAR? agonists (e.g. obesogens) 
have been proposed as treatments for non-alcoholic fatty liver disease and associated insulin 
resistance [554]. Nuclear receptor crosstalk especially at the liver X receptor response 
element is also likely to be important, but is currently understudied. Other proposed 
mechanisms include oxidative/carbonyl stress, endoplasmic reticulum stress, mitochondrial 
dysfunction, increased cytokine production, increased hepatic lipid synthesis/uptake and 
impaired VLDL synthesis and secretion [162, 163]. Many of the environmental chemicals 
associated with steatosis are organochlorines. Of the compounds in the US Environmental 
Protection Agency’s Integrated Risk Information System (IRIS) that induced steatosis in 
rodents following oral (dietary) treatment, the most potent (mirex, chlordecone, chlordane) 
were structurally similar, highly chlorinated molecules (>8 chlorines) [162]. While these 
data suggest that highly halogenated environmental chemicals could be of particular interest 
in steatosis, more data are required.
Key chemical classes identified in adult steatosis studies include solvents and volatile 
organic chemicals; POPs and pesticides; and metals [163, 551]. Solvent exposures have 
historically been associated with steatosis and liver injury in the occupational health 
literature [552, 555]. These data were recently reviewed by the Institute of Medicine and the 
National Research Council which concluded that there was “…evidence of an association 
between chronic exposure to solvents in general and hepatic steatosis that could persist after 
cessation of exposure” [556, 557]. Unfortunately, it is difficult to assess biomarkers of prior 
solvent exposures, and epidemiological data on the impact of solvent exposures in human 
cohorts are lacking.
Exposure to BPA is associated with liver enzyme abnormalities reflective of liver injury in 
population-based studies [344, 558], although pathologic data were not provided. Regarding 
dyslipidemia, non-significant trends were observed for BPA in pediatric NHANES 
populations [559]. However, prolonged (8-month) exposure of male mice to low BPA doses 
induced hypercholesterolemia with upregulation of key genes involved in cholesterol 
biosynthesis including sterol regulatory element-binding protein 2. Whole body de novo 
cholesterol synthesis was also increased as seen by the plasma lathosterol-to-cholesterol 
ratio [503]. Interestingly, the food contaminant 1,3-dichloro-2-propanol induced 
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hyperlipidemia with increased LDL/HDL ratio in mice via the AMP-activated protein kinase 
(AMPK) signaling pathway [560].
Exposures to POPs and pesticides have been associated with fatty liver disease in adults. In 
the NHANES study, PCB exposures were associated with ‘unexplained alanine 
aminotransferase (ALT) elevation’, a surrogate marker for fatty liver [561]. The observed 
association between PCB exposures and ALT was subsequently confirmed in NHANES by 
two other independent groups using different statistical techniques; and also in the 
Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) cohort [562-564]. 
Likewise, associations between organochlorine pesticides or their metabolites and liver 
enzymes have been seen for ALT [562] and gamma glutamyl transferase [565]. 
Perfluorinated chemical exposures were also positively associated with ALT in NHANES 
[566], and this association was more evident for PFOA exposures in obese adults [567]. 
Positive associations were also seen between both PFOA and PFOS exposures in adult 
participants of the C8 study (n=47,092 subjects) [568]. Animal studies of PCBs [160-162, 
535, 551, 569], organochlorine pesticides [162], and PFOA [570] suggest that the liver 
enzyme abnormalities reported in these adult epidemiological studies could be due to fatty 
liver disease.
In population-based studies of hyperlipidemia, PCB exposures were associated with 
longitudinal increases in LDL cholesterol [571]. However, other studies reported nonlinear 
associations between PCBs and organochlorine pesticides with hyperlipidemia [572, 573]. 
PCB treatment has been associated with hyperlipidemia in some [574], but not all rodent 
studies [549]. The chlorinated insecticide, lindane, interacts with ERβ [575], and high-dose 
lindane exposure (12 mg/kg x 20 days) in rats increased serum total cholesterol and 
triglycerides while decreasing HDL cholesterol [576]. On the other hand, TCDD decreased 
total cholesterol, LDL, and HDL in a rodent study suggesting an AhR-mediated serum lipid 
clearance and decreased hepatic efflux [577].
Metals/metalloids have also been associated with abnormal liver function and 
hyperlipidemia. In Bangladesh, drinking from arsenic contaminated wells was associated 
with increased ALT [578]. Chronic arsenic exposures were also associated with increased 
triglycerides in a cross-sectional study [579]; in rats, arsenic increased serum cholesterol, 
triglycerides, free fatty acids and phospholipids in association with increased oxidative stress 
and hepatic mitochondrial damage [580] as well as ALT when combined with an obesogenic 
agent [581, 582]. Lead and mercury exposures were associated with the fatty liver surrogate 
biomarker, ‘unexplained ALT elevation’ in adult NHANES [561]; and lead, but not mercury, 
was associated with ALT, plasma triglycerides and LDL, in Iranian adolescents [583]. In 
mice, however, methylmercury markedly and specifically increased total and LDL 
cholesterol [584]. Cadmium exposures were also associated with ALT in adult Korean 
NHANES participants [585] and Iranian adolescents [586].
Animal studies suggest that the observed ALT elevations in the adult/adolescent populations 
following exposures to arsenic [582], mercury [587], and cadmium [588] may be due to fatty 
liver disease. Thus, data implicate post-developmental exposures to specific volatile organic 
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compounds/solvents, plasticizers, POPs, and metals/metalloids in hepatic steatosis and 
dyslipidemia.
The herbicide, atrazine, is a chloroplast inhibitor which has also been associated with 
mitochondrial dysfunction and NAFLD in rodents[529, 589, 590] Respiratory routes of 
exposure have also been associated with the development of fatty liver disease via the lung-
liver axis. For example, air pollution and particulate matter were associated with 
steatohepatitis in rodents [591, 592], though mechanisms including toll-like receptor 
activation. However, confirmation in human studies is required. While smoking has not 
historically been considered to be a clinically significant factor in the pathogenesis of liver 
disease, recent data demonstrate a link between active and secondhand smoke in the 
development of both adult and pediatric NAFLD[593-596].
5.6.2 Developmental MDC Exposures and Hepatic Steatosis—Given the liver’s 
importance in toxicology, it is somewhat surprising that only scattered evidence exists to 
characterize pathways and patterns of its altered functional development. Nevertheless, a 
number of rodent studies suggest that specific developmental perturbations to liver 
programming may influence the long-term predisposition to steatohepatitis and MetS. Of 
great interest is the multi-generational effect of maternal high-fat feeding, which may prime 
steatohepatitis in adult mice offspring [597-599] (Figure 4). These effects result from 
mechanisms similar to those observed in adult steatohepatitis studies including increased 
lipogenic gene expression with mitochondrial dysfunction and decreased beta oxidation, due 
in part, to altered PPARα/PPAR? expression; microRNA changes; increased oxidative stress 
with reduction in hepatic antioxidant enzymes; and increased inflammation.
Likewise, maternal exposures to chemicals have been associated with altered hepatic 
metabolism and steatosis in offspring. Exposure throughout gestation and perinatal 
development to BPA may further exacerbate the nonalcoholic steatohepatitis-like phenotype 
in male rats that were fed a high-fat diet post-weaning; in particular, BPA worsened the 
accumulation of lipids in hepatocytes as well as liver inflammation and oxidative stress 
fibrosis [600]. Liver function markers were unimpaired in BPA-exposed rats kept on a 
standard diet; however, these animals showed effects suggestive of subtle alterations of liver 
programming, such as moderately increased steatosis and altered expression of insulin 
signaling elements.
Epigenetic changes may be a hotspot in altered liver programming: developmental BPA 
exposure alters gene methylation in mouse liver, in particular concerning genes relevant to 
metabolism and stimulus response. As observed for other molecular and cellular effects of 
EDCs, the effects of BPA were different at low and high dose levels (0.05 and 50 mg/kg bw, 
respectively) [601]. Overall, the findings suggest that the developmentally-induced altered 
liver methylome increased insulin resistance phenotypes in adults. Some of these effects 
may have been related to hepatic changes including altered nuclear receptor expression 
(PPARα/PPAR?) key regulators of energy metabolism, mitochondrial dysfunction, and DNA 
methylation.
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Gestational exposures to, DEHP, also resulted in hepatic steatosis in offspring as well as 
decreased glycogen storage in males, but with a delayed shift to glycogen-dependent 
metabolism of the mature hepatocyte [602]. This phenotype could stem from the DEHP-
PPARα interactions influencing expression of lipid metabolism genes such as microsomal 
triglyceride transfer protein [603]. However, DEHP also interacts with other nuclear 
receptors including CAR and PXR. While there is no direct evidence of the involvement of 
CAR and/or PXR in the DEHP-induced effects on liver metabolic programming, 
nevertheless, their involvement is plausible and deserves attention for potential human 
disease relevance. While DEHP is a less potent human than rodent PPARα activator, it more 
potently activates human CAR [604].
While probably best characterized for plasticizers (BPA, DEHP), developmental exposures 
to other toxicants including benzo[a]pyrene, TBT, PBDEs, and pesticides have also been 
associated with development of fatty liver disease and/or abnormal hepatic lipid metabolism 
in rodents [368, 378, 551, 605]. Rats perinatally exposed to polybrominated diphenyl ether 
47 (PBDE-47) had increased blood cholesterol levels [606]. Altered blood cholesterol was 
likely a result of reduced hepatic Cyp7a1 expression, a critical enzyme for the conversion of 
cholesterol into bile acids [605, 606]. Exposure to BDE-47 and DE-71 (a commercial mix of 
PBDE) resulted in transcriptomic enrichment of genes of lipid metabolism in rat livers [605, 
606], including long-term systematic activation of pathways of α, ω, and β-oxidation of 
fatty acids.
Overall, the available evidence indicates that liver programming may be an important target 
for MDCs that increase predisposition to MetS. Relevant morphological changes include 
increased lipid accumulation and depleted glycogen storage in hepatocytes; changes at 
molecular or biochemical levels may include altered methylation patterns, altered nuclear 
receptor cross-talk, mitochondrial dysfunction, and enhanced free radical production. 
However, more data are needed to define the set of chemicals that result in steatosis and 
dyslipidemia following developmental exposure and the mode of action of these chemicals 
in fatty liver disease. While the animal study data are compelling for developmental BPA 
exposures and steatosis, significant knowledge gaps exist for other MDCs. Epidemiological 
data are also very limited in this area.
5.7 MDCs and Metabolic Syndrome
As noted above there are MDCs that can result in obesity, T2D or lipid disorders. What is 
striking is that when multiple endpoints were examined within individual studies, in many 
cases an MDC caused disruptions in multiple disease pathways leading to what could be 
called MetS. Table 1 shows that indeed many EDCs should be characterized as MDCs as 
they can cause multiple disease/dysfunctions, even when not all of the metabolic endpoints 
were measured in the same experiment. We highlight examples here to show that indeed 
there are MDCs that can affect multiple tissues leading to multiple metabolic disorders and 
in some cases to MetS due to their ability to induce weight gain, glucose intolerance and 
lipid disorders. These data indicate it is important to examine more than one endpoint and 
tissue to define an action of a suspected MDC.
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The first example comes from developmental exposure to BPA, which can induce glucose 
intolerance and insulin resistance [331], and impairments β-cell function and mass [507]. 
Developmental exposure to BPA has also been shown to cause weight gain in offspring in 
some animal models and human studies (reviewed in [340]). BPA exposure throughout 
gestation and perinatal development exacerbates a nonalcoholic steatohepatitis-like 
phenotype in male rats that were fed a high-fat diet post-weaning; in particular, BPA 
worsened the accumulation of lipids in hepatocytes as well as liver inflammation and 
oxidative stress fibrosis [600].
Similarly, rats exposed to DEHP throughout gestation and perinatal development exhibited 
hyperglycemia in the presence of reduced insulin levels [504] along with reductions in β-cell 
mass, reduced islet insulin content, and disruptions in β-cell ultrastructure [491]. Sex-
specific effects of DEHP on measures of insulin resistance have been reported in some 
epidemiological studies[495]. Gestational exposures to DEHP resulted in hepatic steatosis in 
offspring as well as decreased glycogen storage in males, but with a delayed shift to 
glycogen-dependent metabolism of the mature hepatocyte [602]. Prenatal exposure of mice 
to DEHP results in increased body weight as well as numbers and size of adipocytes in male 
offspring in several studies from different labs using different models [356-359].
DDT and its metabolites have been associated with increased risk of higher body weight, 
insulin resistance, T2D and dyslipidemia in human studies [573, 607]. In rodent studies, 
female offspring exposed prenatally to DDT followed by a high fat diet for 12 weeks in 
adulthood developed glucose intolerance, hyperinsulinemia, dyslipidemia and altered bile 
acid metabolism as well as reduced energy expenditure and impaired thermogenesis [389]. 
DDT effects were also transmitted across generations resulting in obesity in the F3 
generation [608].
PBDEs have also been associated with development of fatty liver disease and/or abnormal 
hepatic lipid metabolism in rodent studies [368, 378, 551, 605]. Exposure to BDE-47 and 
DE-71 resulted in transcriptomic enrichment of genes of lipid metabolism in rat livers [605, 
606], including long-term systematic activation of pathways of α, ω, and β-oxidation of 
fatty acids. Developmental exposure in a rodent model to a specific PBDE mixture, 
Firemaster 550, resulted in weight gain in the offspring [410].
Prenatal exposure to TBT in mice promotes adipocyte differentiation that results in 
increased lipid accumulation and adipose tissue while reducing muscle mass that persists 
into adulthood and across generations [309, 367] . It also increases adiposity in zebrafish 
[373] . One epidemiology study noted that prenatal TBT exposures were associated with a 
non-significant trend towards higher weight gain in the first three months of life [374]. In a 
transgenerational study, TBT resulted in hepatic steatosis through the F3 generation. Finally 
TBT was shown to promote hyperglycemia with reduced circulating insulin levels 
accompanied by increased islet apoptosis and reduced cellular proliferation, suggesting a β-
cell defect as a contributing lesion to TBT-induced metabolic dysfunction [476].
Among the other chemicals summarized in table 1, developmental exposure to PAHs in a 
rodent model induce obesity, insulin resistance and inflammation in adults on a high fat diet 
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[376] [377]. In a human cohort, children of mothers with the highest PAHs exposure during 
pregnancy had increased weight at 5 and 7 years of age [379]. Prenatal exposure to specific 
PCB congeners in birth cohort studies was shown to result in increased BMI in offspring 
[387] [390, 393]. Arsenic also deserves mention because of its specific association with 
insulin dysregulation and T2D and liver toxicity [477, 522, 528, 582]
5.8 MDCs and Transgenerational Metabolic Disruption
A variety of stressors including high-fat, high-sugar diets, low protein diets and 
environmental chemicals can induce transgenerational inheritance of metabolic diseases 
[609]. Several recent papers have shown that the effects of MDC exposure in pregnant F0 
animals were propagated until at least the F3 generation (reviewed in [309, 610, 611]). This 
is significant because when exposures occur in the maternal lineage, the F0 and F1 animals 
are directly exposed to the chemical and the F2 generation is exposed as germ cells within 
the gestating F1 animals. The F3 generation is the first generation that has not received any 
direct chemical exposure; therefore, effects observed in F3 and beyond are considered to be 
transgenerational and permanent, and are distinguished from the multigenerational effects in 
F1 and F2 animals [612].
Exposure of pregnant F0 animals to low, environmentally-relevant levels of TBT in their 
drinking water led to increased fat depot size, MSCs reprogrammed toward the adipogenic 
lineage and hepatic steatosis through the F3 generation [368]. Effects on fat depot size were 
more pronounced in F1 females than F1 males. Prenatal TBT exposure permanently alters 
MSC cell fate in both males and females and caused hepatic steatosis and altered hepatic 
gene expression in both males and females through the F3 generation. Skinner and 
colleagues have similarly shown that plastic components such as BPA, DEHP, dibutyl 
phthalate [358], a mixed hydrocarbon mixture (jet fuel JP-8) [358], and DDT [358] all lead 
to a transgenerational predisposition to obesity in the F3 generation. The molecular 
mechanisms remain unclear; however, many of the toxicants work through nuclear receptors 
[611] that are likely linked to epigenetic changes [613, 614] that likely play a significant role 
in the transgenerational effects. Imprinting, altered DNA methylation, histone modifications 
and copy number variants have all been implicated in transgenerational phenotype 
transmission as a result of exposure to chemicals or altered nutrition [610] [615-617]. 
Candidate sperm epimutations were also identified that could be involved in the etiology of 
the transgenerational obesity and other disease outcomes [618].
6. Conclusions: A Perfect storm for Metabolic Disease
Many of the studies discussed above highlight the importance of development as a sensitive 
time for programming all aspects of metabolism. Environmental chemicals with endocrine 
activity can alter programming of metabolism; this fact, along with the importance of diet 
during development and throughout life on metabolism, and the role for exercise in 
controlling weight and glucose metabolism, leads to the perfect storm for metabolic disease. 
In utero, and the first few years of life, are critical periods where the sensitivity or set point 
for obesity, diabetes and liver disease are established. We have herein shown that sensitivity 
or set points for the development of these diseases can be altered by MDCs that interfere 
Heindel et al. Page 38
Reprod Toxicol. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
with the normal developmental trajectories of adipose tissue, pancreas, muscle, liver, GI 
tract and the brain. These set points are also influenced by diet and nutrition in utero and 
early childhood years, thus nutrition and MDC exposures during development are the key 
along with genetic background for setting the stage for all metabolic diseases.
These metabolic diseases may not manifest until later in life when the system is challenged 
by over-nutrition and/or lack of exercise. MDCs can change the expression of genes 
involved in the control of adipogenesis as well as glucose and lipid metabolism. Exposure to 
MDCs, together with excess calories and lack of exercise, would increase the susceptibility 
to these disease epidemics. Thus, we propose that some individuals are more prone to gain 
weight due to both their genetic background and the effects of developmental exposures to 
MDCs that are critical for setting the sensitivity or susceptibility of the tissues for metabolic 
disruption later in life.
Some recent publications support increased susceptibility to obesity due to environmental 
exposures. Developmental exposure to BPA induced weight gain due to increased food 
intake, changes in brain satiety neurons [619] and decreased activity and energy expenditure 
in females [620]. Similarly, prenatal nicotine leads to increased body weight due to a marked 
hypertrophy of adipocytes and fat deposition along with decreased spontaneous physical 
activity later in life, cold intolerance, and also increased sensitivity to the effects of high fat 
diet [313]. In addition, there are many examples of the effects of developmental exposures to 
MDCs that are exacerbated by high fat diet later in life, again indicating that developmental 
exposures increase the susceptibility to obesity (and other metabolic diseases) but may need 
a “second hit” later in life for the effects to actually become apparent as disease. For 
example, developmental exposure to PAH results in obesity, insulin resistance and 
inflammation only after a high fat diet as adults [376] [377]; the effect of atrazine on insulin 
resistance was exacerbated by high fat diet [529]; and BPA-induced insulin resistance may 
be additive with high fat diet [331]. Thus there are emerging data supporting a role for 
developmental exposures to MDCs in altering the set point of susceptibility for metabolic 
diseases later in life. The second hit of high fat diet and lack of exercise then results in onset 
of the metabolic diseases.
Of course, throughout life there are likely to be multiple exposures to MDCs that can also 
increase sensitivity to metabolic disruption leading to weight gain, altered glucose tolerance 
and lipid disorders. For example, young mice exposed to BPA for 30 days showed 
significantly increased body weight and fat mass on a chow diet [332] but not on HFD 
(45%) which could be due to the overwhelming effect of the HFD. If true, then it would be 
difficult to control or treat metabolic disorders with pharmaceuticals later in life, as they 
would need to be able to offset the increased sensitivity programmed during early 
development. Indeed, the current state of science and medicine focuses on losing weight, 
and restoring glucose homeostasis and liver lipids after they are disrupted; it is clear that this 
approach is not working as the incidence of these diseases continues to increase. 
Furthermore, it is well documented that while it is possible to lose weight and keep it off for 
an extended time, the vast majority of people will gain the weight back, perhaps indicating 
they are fighting against a set point or sensitivity to develop these metabolic problems that 
favors calorie storage over the long term [437, 438, 621, 622].
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For this reason, a consequence of the MDC hypothesis is that a focus should be on 
prevention instead of intervention. If indeed a set point for body weight, diabetes and/or 
METS is developed in early life, then a better approach would be to focus on limiting factors 
that can alter programming during these sensitive times; for example, addressing these 
metabolic epidemics will require reducing MDC exposures and improving early-life 
nutrition. In this way, the MDC hypothesis offers the ability to actually prevent these 
diseases, which is more cost effective and public health protective than the current focus on 
interventions after the diseases are apparent. Primary prevention measures must include up-
to-date regulation of chemicals: robust tools are needed in order to identify MDCs among 
existing as well as new chemicals.
The MDC hypothesis proposes both a mechanism for the increased epidemic of obesity, 
diabetes and MetS and a solution. If indeed these diseases are due in part to developmental 
exposures to MDCs, as proposed, then for the first time there is a path to actually preventing 
them. The MDC hypothesis changes the focus from genetics to environmental exposures and 
from intervention to prevention.
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Highlights
• The recent epidemics of metabolic diseases, obesity, type 2 diabetes and liver 
lipid disorders cannot be attributed only to genetic background, and changes 
in diet, exercise and aging.
• Metabolic diseases, like many other diseases, have their origins during 
development due to altered programming that increases susceptibility to these 
diseases. Some effects can be transmitted across generations.
• Since metabolic diseases are controlled and regulated by hormones during 
development and throughout life, they are sensitive to disruption by chemicals 
that can interfere with hormone action: endocrine disruptors.
• We propose that there are environmental chemicals that increase the 
susceptibility to metabolic diseases via actions on adipose tissue, pancreas, 
liver, GI tract, muscle and brain homeostatic and hedonic pathways and that 
these chemicals should be called metabolism disrupting chemicals (MDC) or 
metabolism disruptors.
• MDCs can act on multiple tissues to increase susceptibility to obesity, T2D 
and liver lipid disorders resulting in metabolic syndrome while others may be 
tissue specific resulting in only one metabolic disease depending on their site 
and mechanism of action.
• While some MDCs can actually cause metabolic diseases per se many act via 
increasing the sensitivity or susceptibility to disease (e.g. alter set point for 
disease) and require a “second hit” later in life like high fat diet or lack of 
exercise. There are now data in animal models showing how MDCs can alter 
the set point for metabolic diseases. For example how much food it takes to 
gain weight and how much exercise is needed to lose weight…mimicking the 
human situation.
• The MDC hypothesis along with the fact that development is the most 
sensitive period for MDC action provide a mechanism for actually preventing 
metabolic diseases: reduce exposure to MDCs during development and across 
the lifespan.
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Figure 1. Schematic illustrating the neuroendocrine control of energy balance (modified from 
Schwartz et al Nature 404, 661-71, 2000)
Peripheral signals reach the central nervous system through two main routes:
Adiposity Signals (leptin, insulin and others) and hunger (Ghrelin, Orexin A, and others) 
signals bypass the blood brain barrier and target the hypothalamus (transparent blue circle), 
in particular the arcuate nucleus (ARC).
b) Peripheral hunger and satiety signals that control meal processing, gastrointestinal activity 
and changes in energy stores reach the brainstem (nucleus of the solitary tract, NST) through 
vagal and other sensory nerve fibers.
NPY and MSH neurons located within the ARC (stimulated or inhibited by adiposity and 
hunger signals) project to other hypothalamic nuclei (paraventricular nucleus, PVN, lateral 
hypothalamic nucleus, LH, and others). In particular, within the PVN they control CRH and 
TRH neurons, regulating (via the adenohypophysis) the hypophysis-adrenal and hypophysis-
thyroid axes.
From the hypothalamus, catabolic and anabolic pathways reach the brainstem where their 
data are integrated with the peripheral signals carried by the sensory system. There are also 
ascending projections from the NST that may reach the hypothalamus, through the 
lemniscus visceralis, contributing to adaptative changes in food intake and energy 
expenditure.
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Figure 2. Mechanisms of Adipocyte Formation and Sites of Action of Metabolism Disruptors
1. Mesenchymal stem cells commit to the adipogenic lineage and become preadipocytes. 
Commitment to the adipocyte lineage is mediated by transcription factors Zfp423, Zfp467, 
Schnurri2, Tcf7l1 and the mTORC1 effector S6K1. 2. Adipocyte differentiation is primarily 
controlled by PPARγ and CCAAT-enchancer binding proteins (C/EBP)α, β and δ which 
establish a sustained feedback loop. Numerous chemicals are capable of differentiating pre-
adipocytes into mature adipocytes. Adipocyte number and size can be increased in vivo 
under hormonal control and can also be influenced by chemical exposure. 3. Adipocyte 
hyperplasia has been shown in rodents to be caused by perinatal exposure to a variety of 
chemicals. 4. Adipocyte hypertrophy in rodents due to permanent upregulation of genes 
involved in lipid uptake is also caused by exposure during perinatal life to a number of 
chemicals.
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Figure 3. Regulation of pancreas beta cell control of blood glucose and sites of action of 
metabolism disruptors
Glucose enters pancreatic beta-cells through glucose transporters (GLUT2 in mice and 
GLUT1 in humans) where it is metabolized in mitochondria resulting in an increase in the 
ATP/ADP ratio; this results in closure of membrane ATP-sensitive K+ channels (KATP) that 
are responsible for the resting membrane potential. KATP channel closure results in cellular 
depolarization that opens voltage-gated calcium channels, triggering Ca2+ signals that 
induce insulin granule exocytosis and a subsequent rise in circulating insulin levels. This 
secretory pathway is disrupted by EDCs at different points: 1) Bisphenol-A, nonylphenol, 
octylphenol and triphenyltin impair mitochondrial function. 2) Bisphenol-A blocks KATP 
channels after binding ERbeta. 3) Calcium signaling is altered by Bisphenol-A, Arsenic, 
PCBs and Triphenyltin. 4) disruption of insulin secretion has been described for Bisphenol-
A, dioxins, PCBs, DDT, Arsenic, and Cadmium . Beta-cells have a low antioxidant capacity 
and are very sensitive to oxidative stress mediated by reactive oxygen and nitrogen species 
that impair their function by altering metabolism and/or KATP activity while inducing 
apoptosis. Mercury and Cadmium (5) are EDCs that produce oxidative stress in beta-cells. 
6) Insulin gene expression is regulated by BPA via ERα, while DEHP and Cadmium 
provoke cell death and decrease in beta-cell mass.
Heindel et al. Page 72
Reprod Toxicol. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. Regulation of hepatic lipid metabolism and sites of action of metabolism disruptors
Hepatic steatosis occurs due to a combination of increased fatty acid (FA) synthesis or 
uptake and decrease FA oxidation or efflux. FA synthesis occurs as a consequence of liver X 
receptor (LXR) target gene activation which may occur following receptor activation by 
myriad environmental chemicals or via nuclear receptor cross talk. FA synthesis is 
upregulated by BPA, metals, PFCs, POPs, and tributyltin. BPA and POPs also upregulate 
scavenger receptors (e.g. CD36) to increase FA uptake into hepatocytes. Decreased FA 
oxidation is a consequence of mitochondrial dysfunction which may be mediated by BPA, 
chlorinated solvents POPs and metals. Liver also mediates xenobiotic metabolism which 
may increase oxidative stress. Endoplasmic reticulum (ER) stress is a consequence of 
exposures to aldehydes and metals. ER stress, in turn, impacts FA metabolism. 
Steatohepatitis occurs due to increased hepatic inflammation and cytokines. 
Proinflammatory cytokines are induced by many exposures including POPs, vinyl chloride, 
VOCs, and metals. More data are needed on the impact of MDCs on FA efflux in hepatic 
steatosis.
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Table 1
Metabolism Disruptors and Metabolic Disruption
Chemical Obesity T2D Lipid Disorders
Chemical Obesity T2D Fatty Liver
Bisphenol A *** *** ***
DEHP *** *** ***
DDT/DDE *** ** *
PBDE *
PFOA ** ***
PFOS * ***
TBT *** *** ***
Air Pollution ** *** ***
PAHs
PCBs * *** ***
TCDD ** ***
Cadmium * **
Atrazine * **
Arsenic ** *** ***
HCB *
Trifumizole *
Benzo(a) pyrene * **
Tolyfuanid * *
Smoking/nicotine *** ** ***
This table has been developed from the literature cited in this review. The number of *** indicates the strength of the evidence.
*indicates one manuscript animal or human,
**indicates one manuscript in animal and human or more than one manuscript in either animal or human
***indicates more than one manuscript in both animal and human studies, or multiple manuscripts in animal studies.
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